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Abstract 
In humans, MsrB3 occur in two different isoforms, which is a distinct characteristic 
found in no other organism. MsrB3A is the MsrB3 isoform which is localised within the 
endoplasmic reticulum of the human cell, while, the MsrB3B isoform is found in the 
mitochondria along with MsrB2. The primary role of MsrB3A is to repair the oxidised 
methionine residues in nascent polypeptides and the unfolded protein chains found in the 
endoplasmic reticulum, which become oxidised by ROS species produced within the 
endoplasmic reticulum.  However, the exact mode of action of MsrB3A and the stereo-
specificity of MsrB3A is not entirely clear. 
Hence, this thesis aims - (i) to determine the structure of MsrB3A, and (ii) to find 
out the functionality and stereospecificity of MsrB3A protein. The mature gene sequence 
for MsrB3A protein lacking the sequence for the N-terminal signal peptide was successfully 
cloned into recombinant E. coli cells and subsequently over-expressed to generate the 
recombinant MsrB3A protein for further studies.  
From a sequence alignment, it was predicted that the 126th position cysteine residue 
in the amino acid sequence of MsrB3A was an active site cysteine and responsible for the 
function of the protein, as it was a conserved residue. Based on this assumption, the 126th 
position cysteine was substituted with alanine residue using site directed mutagenesis to 
generate a mutant protein which could be further used in determination of protein 
activity. 
With respect to determination of MsrB3A structure, we used three approaches- (i) 
CD Spectroscopy for determining the secondary structural elements of MsrB3A, (ii) NMR 
spectroscopy and (iii) protein crystallisation to determine the tertiary structure of MsrB3A 
protein.  
The results obtained from CD spectroscopy and NMR spectroscopy proved that the 
recombinant MsrB3A protein had a folded structure. It was also noted that the results 
which were obtained by CD spectroscopy were consistent with previous studies performed 
by other groups with respect to MsrB proteins.   Though certain crystallisation hits were 
obtained, good quality crystals required for determining the crystal structure by X-ray 
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spectroscopy were not achieved, hence, the crystal trials were not successful and requires 
further work. 
To address the functionality of MsrB3A, two different approaches were used- (i) a 
gel shift assay and (ii) a HPLC assay. The gel shift assay involved the change in mobility of 
SurA protein in its oxidised and reduced states which formed the basis of determining the 
protein functionality, when analysed on SDS-PAGE gel. Hence, when SurA was oxidised by 
treatment with H2O2, the mobility of SurA decreased with respect to its native form when 
analysed on SDS-PAGE gel. Hence, when the oxidised form was repaired by treatment with 
MsrB3A protein in presence of DTT, there was a slight shift in the mobility of oxidised SurA 
towards its native form, but could not gain complete mobility, suggesting an incomplete 
repair and indicating that MsrB3A is stereo-specific, but cannot say which isoform of 
methionine sulfoxide it reduces. Similar results were also achieved by HPLC assay in which 
approximately half of the dabsylated methionine sulfoxide concentration was reduced to 
dabsylated methionine, which supports and suggests that MsrB3A is stereo-specific, but 
further experiments using individually dabsylated methionine-R-sulfoxide and methionine-
S-sulfoxide is required as substrate to have accurate determination of stereo-specificity. 
Another significant observation which was made by the HPLC assay was the non-
functionality of the C126A MsrB3A mutant protein. When the dabsylated methionine 
sulfoxide was treated with the C126A MsrB3A mutant no reduction was observed upon 
separation using the HPLC. This indicated that the cysteine residue being substituted was 
an active site cysteine which is responsible for the protein function.  
Therefore, to conclude, we could gain a stable recombinant protein product which 
could be actively used for study and experimentation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
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Figure 1.1:  Chemical structures of cysteine and methionine residue. 
The chemical structure in blue represents the basic amino acid backbone. The alkyl group which defines 
the amino acid is represented in red. The alkyl group of cysteine contains a sulfhydryl group (-SH), while 
in methionine the sulphur atom is contained within the alkyl chain. 
 
Chapter 1: Introduction 
General introduction 
It is well known that cysteine, homocysteine, methionine and taurine are the 
sulphur containing amino acids which occur in nature, but only cysteine and methionine 
(Fig. 1.1) are the two-sulphur containing amino acids that are naturally incorporated into 
proteins. From the literature, the major functions of cysteine are widely known and 
studied. Cysteine plays a vital role as active site residues in many enzymes like proteases, 
phosphatases and proteinases for enzyme catalysis, provides structural support to many 
proteins via disulphide linkages, or acts as antioxidants to help in redox recycling of 
glutathione and thioredoxin and many other such vital functions.  
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On the other hand, the most well-known function of methionine is its vital role as 
initiator of protein synthesis. Yet from studies, it has been found that methionine can also 
act as an effective antioxidant (Levine et al., 1996) and also helps in regulation of cellular 
function via redox reactions in the cell (Gonias et al., 1988, Brot and Weissbach, 1991, 
Vogt, 1995).  However, to keep up the role of antioxidant the oxidised methionine must 
also be recycled back to its reduced state. This is done by a specialised set of enzymes 
called methionine sulfoxide reductases (Msrs), which are then subsequently reduced either 
by thioredoxin or glutathione following NADP(H) reducing pathway. The role of methionine 
to regulate cellular activities are further discussed in the following sections. 
 
1.1 Methionine as an antioxidant 
From previous studies, it has been determined that methionine residues 
present at the protein surface acts like antioxidants protecting the host protein 
against ROS-induced oxidative stress, thereby, helping the host proteins to retain 
their activity, for example, in α-2-macroglobulin the surface bound methionine 
residues actively become oxidised by ROS-species to protect the critically important 
tryptophan residue present in the active site, thereby, acting as an antioxidant 
(Reddy et al., 1989, Reddy et al., 1994). Another good example of the antioxidant 
function of surface bound methionine residues in proteins are the high density 
lipoproteins which reduce cholesteryl ester hydroperoxides to alcohols with 
concomitant oxidation of two methionine residues to methionine sulfoxides (Garner 
et al., 1998).   
However, in the case of unfolded proteins and nascent polypeptides the 
situation is not the same. From studies, it has been noted that the sulphur atom of 
methionine residues within unfolded proteins gets readily attacked by reactive 
oxygen species (Fig. 2), thereby, converting them to methionine sulfoxides (Levine 
et al., 1996, Nakao et al., 2003). This oxidation, in turn, can cause changes in 
hydrophobicity of proteins (Chao et al., 1997, Levine et al., 1996, Vogt, 1995) or 
major conformational changes in the oxidised proteins that may result in 
dysfunctional or non-functional protein molecules; hindering essential cellular 
activities (Vogt, 1995, Berlett et al., 1998, Sigalov and Stern, 1998, von Eckardstein 
et al., 1991). A direct result of the accumulation of dysfunctional or non-functional 
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Figure 1.2:  ROS-induced oxidation of methionine (Met) residue to methionine sulfoxide (Met-SO) 
and further oxidation by ROS species to methionine sulfone. (Picture is taken from Drazic, 2014) 
Met residues on exposure to ROS species gets readily oxidised to Met-SO. At higher concentrations of 
ROS species and absence of repair mechanism, the Met-SO gets further oxidised to methionine sulfone.  
proteins is the increase in ROS species, leading to increased oxidative stress. 
Another direct consequence of prolonged accumulation of oxidised methionine 
residues is the formation of free radicals, such as methionine sulfone, with greater 
oxidative potential (Fig. 1.2). In humans, accumulation of such free radicals, 
especially in the brain, leads to neurodegenerative disorders like Alzheimer’s 
disease, which degrades the nerve cells in the brain (Butterfield and Kanski, 2002, 
Schoneich, 2002). It has also been predicted that excessive methionine oxidation 
may result in conformational switches between the α-helical and ß-sheet structures, 
like those occurring in neurodegenerative disorders like in Alzheimer’s disease, 
Parkinson’s disease, etc., (Dado and Gellman, 1993, Nakao et al., 2003). Similar 
situations have also been reported in genomic studies related to cancer. It was 
noted that down-regulation of methionine sulfoxide genes within human breast 
cancer cells, increased the proliferation rates of the cancer cells along with rapid 
degradation of the extracellular matrix (De Luca et al., 2010).      
 
 
 
 
 
Hence, to recycle the activity of surface bound methionine residues, as well 
as, to repair and protect the oxidised methionine residues in unfolded proteins and 
nascent polypeptides, an endogenous group of repair enzymes called methionine 
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sulfoxide reductases (Msrs) are present within the cells, which actively reduce the 
methionine sulfoxide to methionine. This helps to restore the antioxidant properties 
of surface bound methionine residues, as well as, themselves acting as antioxidants, 
protecting unfolded proteins and nascent polypeptides against ROS-induced 
oxidative stress. Methionine sulfoxide reductases are discussed further in detail in 
the next section. 
 
1.2 Methionine sulfoxide reductases (Msrs) 
Methionine sulfoxide reductases are a group of oxidoreductase enzymes that 
act like antioxidants and protect the proteins against ROS induced oxidative stress. 
Hence, the methionine sulfoxide reductase (Msr) proteins help in regulating protein 
function, can be involved in signal transduction and prevent accumulation of faulty 
proteins lowering the chances of further oxidative stress. Any malfunction or down-
regulation in the expression of the Msr enzymes results in compromised antioxidant 
defence, enhanced age-associated disorders such as neurodegeneration and reduced 
life-span (Moskovitz, 2005).  
Whenever methionine residues get oxidised by reactive oxygen species, a 
racemic mixture of stereoisomers of methionine sulfoxide are formed- methionine-S-
sulfoxide and methionine-R-sulfoxide (Schöneich et al., 1993). Due to the formation 
of two different stereoisomers of methionine sulfoxide, methionine sulfoxide 
reductases are also grouped into 2 major categories- MsrA which catalyses the 
reduction of methionine-S-sulfoxide and MsrB which catalyses the reduction of 
methionine-R-sulfoxide (Fig. 1.3) (Lowther et al., 2002, Grimaud et al., 2001, 
Moskovitz et al., 2000, Moskovitz et al., 2002, Singh et al., 2001, Stadtman et al., 
2003). Besides the two major forms of Msrs, a third group is present in eubacteria 
and unicellular eukaryotes in minute quantities, which could selectively reduce free 
methionine-R-sulfoxides (Boschi-Muller and Branlant, 2014). Both these enzymes are 
vital for protecting the proteins against toxicity of reactive oxygen species by 
preventing excessive accumulation of oxidised proteins within the cells. Therefore, 
they are found in almost all living organisms, starting from bacteria to plants and 
mammals as discussed further in chapter 3.  
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Figure 1.3:  Oxidation of methionine to methionine sulfoxide and reduction pathway of 
methionine sulfoxide to methionine. (Picture taken from Kim, 2007). 
Free or protein bound methionine residues present on protein surface or in nascent polypeptides 
are readily oxidised by ROS (shown in spiky red shape) to form mixture of diastereomers of 
methionine sulfoxide. Methionine-S-sulfoxides stereospecifically reduced by MsrA (shown in solid 
blue circle), while MsrB (shown in solid purple circle) reduces methionine-R-sulfoxides to 
methionine, respectively, in the presence of reducing agents like- DTT or thioredoxin reduction 
system.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Apart from the antioxidant function, Msrs have been shown also to regulate 
protein function by switching the activation and inactivation of specific methionine 
residues within protein molecules. For example, the potassium channels of neurons 
have been seen to be somehow regulated by the expression of MsrA (Ciorba et al., 
1997). Similar cases have also been noted in the regulation of calmodulin activity 
(Sun et al., 1999).  Hence, the significance of Msrs in the cells can be well 
established from above. 
 
1.3 Methionine sulfoxide reductases and diseases 
As discussed earlier, any disruption or loss in the enzymatic activity of 
methionine sulfoxide reductase enzymes has negative impact on cellular functions 
caused by loss of antioxidant function and disruption in the regulation of activity of 
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various proteins. From various genomic studies conducted in different organisms, it 
has been observed that loss or mutation of the msr genes leads to increase in 
oxidative stress, along with reduced life span. In humans, it has been predicted to 
be indirectly responsible for diseases, such as, neurodegenerative disorders like 
Alzheimer’s disease, Parkinson’s disease, etc., and other diseases like cancer, age- 
related deafness, etc. These have been discussed further in the subsequent 
paragraphs. 
A recent study conducted on the methionine sulfoxide reductase enzymes of 
important human pathogens such as E. coli and Pseudomonas aerugonisa, has shown 
that the novel MsrPQ system played a vital role in protecting important perisplasmic 
proteins (Goemans et al., 2014, Silhavy et al., 2010), which help in the assembly of 
proteins in the periplasmic space of the bacterial cell wall (Gennaris et al., 2015), 
against the oxidative stress induced by reactive oxygen species (ROS). Besides 
identification of new and novel Msrs in bacterial cells, the structure and mode of 
action of bacterial Msrs have been well determined throughout literature.  
But in case of higher organisms, the situation is not the same. This can be 
attributed to the complexity of the different cellular compartments in the 
eukaryotic cells owing to difference in the expression of the proteins. Although in 
higher organisms, not much progress has been made with respect to the structure 
and mode of action of the different Msrs present in different compartments of the 
cell, yet from expression studies conducted on yeast, plants, fruit flies (Drosophila 
spp.), and mammalian cells, it was observed that the cells in which the msr genes 
were over-expressed showed greater resistance to ROS-induced oxidative stress and 
had longer life-spans (Moskovitz et al., 1997, Moskovitz et al., 2002, Kryukov et al., 
2002, Kumar et al., 2002, Kwak et al., 2012). 
In humans, methionine oxidation can indirectly be associated with many major 
disorders, especially, neurodegenerative disorders like Alzheimer’s disease, 
Parkinson’s disease, Creutzfeldt-Jakob disease, etc. The association of the 
neurodegenerative disorders with methionine oxidation is discussed as follows.  
In Alzheimer’s disease, oxidation of the 35th methionine residue in the ß-amyloid 
peptide in the brain leads to the process of formation of free radicals at higher rates 
within the brain’s nervous tissue, leading to toxicity and conformational changes 
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(Butterfield and Kanski, 2002, Schoneich, 2002, Pogocki, 2003, Schöneich et al., 
2003). In a study, it was also observed that, with increase in the free radical 
formation and protein modification of the ß-amyloid peptide caused by the reduced 
activity of MsrA protein in the brain, re-fibrillation of the ß-amyloid peptide in 
presence of metal ions occurs which could further aggravate Alzheimer’s disease 
(Gabbita et al., 1999). In case of Parkinson’s disease, methionine oxidation has a 
more direct effect. The oxidation of methionine residues in α-synuclein protein 
causes the protein to lose its fibrillation (Uversky et al., 2002). However, it was also 
noted that on continued exposure the oxidised methionine residue might get further 
oxidised to form methionine sulfone (Fig. 1.2), which might lead to the oxidation of 
other amino acids present in the α-synuclein protein in presence of metal ions. This 
in turn would cause re-fibrillation of the α-synuclein protein, leading to progression 
of Parkinson’s disease (Yamin et al., 2003).  
Recent studies have also shown loss of MsrA antioxidant activity leads to 
aggressive progression of breast cancer and degradation of the extracellular matrix 
(De Luca et al., 2010). It has also been noted that mutation or inhibition of msrB 
gene in humans may cause deafness, which progresses with age (Ahmed et al., 
2011). Hence, it can be said that methionine sulfoxide reductases are essential not 
only as an antioxidant but also in regulating vital cellular activities performed by the 
proteins.  
As we discussed earlier, methionine sulfoxide reductases occur mainly in 2 broad 
categories- MsrA and MsrB, whose function, type, distribution and mode of action of 
the proteins are discussed in detail in the following sub-sections.  
 
1.4 Methionine sulfoxide reductase isoform A (MsrA) 
As stated earlier, methionine sulfoxide reductase isoform A or MsrA are a 
group of oxidoreductase class of enzymes which can effectively reduce methionine-
S-sulfoxide to methionine. But to maintain the antioxidant functions, the Msrs need 
to be recycled back to their active forms. Hence, different reducing pathways are 
present in different organisms to recycle the activity of Msrs, such as, by help of 
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respiratory chain electrons, thioredoxin-thioredoxin reductase-NADPH based 
reduction pathway, etc. (Gennaris et al., 2015, Gonzalez Porque et al., 1970).  
Throughout the literature, the functionality of MsrA, its mode of action and 
structure are widely known due to the widespread studies conducted on it. As we 
know from the previous section, Msrs or Msrs coupled with methionine residues in 
certain cases play important roles in providing antioxidant defence against reactive 
oxygen species (ROS), as well as, in some cases also help in regulation of protein 
function or helps in protein folding. Hence, it is quite evident that MsrA should be 
present throughout the cell comparments in both prokaryotic and eukaryotic cells to 
promote proper functioning of cellular activities.  
Most organisms starting from bacteria to higher organisms like mammals, all 
contain the MsrA and MsrB genes within their genome. Yet thermophiles that grow in 
extremely hot locations, lack MsrA, MsrB or both the genes, suggesting that the 
proteins might be essential for organisms living at moderate temperatures (Kryukov 
et al., 2002). In bacterial genomes, both the MsrA and MsrB genes are clustered and 
linked with each other within the bacterial plasmid. Hence, they tend to occur in 
close association with each other (Kryukov et al., 2002, Ezraty et al., 2005). Yeast 
(Saccharomyces cerevisiae), other unicellular eukaryotes and Drosophila spp. Have 
only a single gene each for both MsrA and MsrB (Kryukov et al., 2002). But plants 
contain multiple sets of genes for both MsrA and MsrB proteins (Bechtold et al., 
2004, Vieira Dos Santos et al., 2005, Novoselov et al., 2002). In mammals, the MsrA 
protein has only a single gene, but MsrA protein is transported to the cytosol, 
nucleus or mitochondria depending on the alternative splicing of it N-terminal signal 
peptide, which is responsible for directing MsrA to its target location (Kim and 
Gladyshev, 2005b, Black, 2003). 
As mentioned earlier, MsrA is the most widely studied methionine sulfoxide 
reductase enzyme. Hence, its structure and series of reaction which takes place at 
the active site is known in detail and well understood (Boschi-Muller and Branlant, 
2014). Though the mode of action for reducing methionine sulfoxide to methionine is 
different for different Msr isoforms, but all Msrs follow the same sulfenic acid 
pathway for the reduction of methionine sulfoxide to methionine, with the help of a 
catalytic cysteine residue present at the active site of the enzyme (Boschi-Muller et 
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al., 2000, Boschi-Muller et al., 2005). When the substrate binds at the active site of 
the enzyme a nucleophilic attack is initiated by the catalytic cysteine on the S-atom 
of the sulfoxide molecule. Simultaneously, protonation of the oxygen atom in the 
sulfoxide molecule occurs producing a sulfurane intermediate in the reduction 
process. This reaction step also serves as the rate-limiting step during the formation 
of the sulfenic acid intermediate (Fig. 4). From 3D structural analysis of MsrA in 
complex with substrate, it is found that the oxygen atom of sulfoxide molecule is 
stabilised by hydrophilic amino acid residues that comprise of a network of H-
bonding interactions at the active site of the enzyme (Ranaivoson et al., 2008). This 
aids in the catalytic activity of active site cysteine and help produce the sulfenic 
acid intermediate (Boschi-Muller and Branlant, 2014).  
 
1.5 Methionine sulfoxide reductase isoform B (MsrB) 
Methionine sulfoxide reductase isoform B or MsrB constitutes the second 
major group of Msrs which are responsible for the reduction of methionine-R-
sulfoxide to methionine. Although, in most organisms, the MsrB is present mainly in 
a single form in close association with MsrA to reduce the entire racemic mixture of 
methionine sulfoxide to methionine, the MsrB differ from each other in different 
organisms and have different amino acid sequences. A common feature of most MsrB 
is the presence of a conserved resolving cysteine residue present towards the N-
terminal of the amino acid sequence (Fig. 3.1). In contrast to the above, MsrB 
protein exists in three different forms in mammalian cells (Jung et al., 2002, 
Kryukov et al., 2002, Stadtman et al., 2003). Table 1.1 illustrates the differences in 
the different types of MsrB isoforms that occur in the mammalian cells. MsrB1 (or 
SelR) is the MsrB isoform in mammalian cells that is localised within the nucleus and 
cytoplasm, and is specialised due to the presence of a selenocysteine residue at the 
active site that helps in the protein function. Due to the presence of the 
selenocysteine residue, the protein is about 1,000 X more active than MsrBs in 
general (Kim and Gladyshev, 2005a). MsrB2 (or CBS-1) and MsrB3 are the two other 
MsrB proteins found in mammals and are localised within the mitochondria and 
endoplasmic reticulum, respectively. However, in humans, the MsrB3 occur in two 
different isoforms- MsrB3A and MsrB3B- which is a unique feature that is observed in 
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no other organism. It is also surprising to note that MsrB3B is localised in the 
mitochondria and is also a unique feature, in which two different MsrB isoforms are 
present to regulate cell function and antioxidant defence. On the other hand, 
MsrB3A is localised within the endoplasmic reticulum and is responsible in protecting 
the nascent and unfolded polypeptides against ROS induced oxidative stress within 
the endoplasmic reticulum. Hence, the significance of MsrB proteins would be 
further discussed in detail in chapter 3. 
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Table 1.1: Different isoforms of MsrB in mammals.   
 
MsrB1 MsrB2 MsrB3 
Localised in the nucleus 
and cytoplasm. 
Present in the mitochondria. 
Localised within the 
endoplasmic reticulum. 
 
Contains modified amino 
acid- selenocysteine at 
the active site and helps 
in protein function. 
 
Has normal cysteine residue 
at its active site to help in its 
function. 
Also has cysteine residue at its 
active site to help in its 
function. 
 
It is 1000 times more 
active than other MsrB 
isoforms, due to the 
presence of 
selenocysteine. 
 
Inhibited by substrate 
concentrations above 1 mM. 
Active for substrate 
concentrations above 1 mM. 
Has well defined crystal 
structure and mode of 
function has been well 
established. 
Has no definite crystal 
structure yet, though an NMR 
ensemble has been 
determined for mouse MsrB2. 
 
No structural data available till 
now. 
Exists as a single isoform. Exists as a single isoform. 
Exists as a single isoform in 
most mammals. In humans, it 
again has two forms- MsrB3A 
(localised in the ER) and 
MsrB3B (found in the 
mitochondria) because of 
alternative splicing. 
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Figure 1.4:  Schematic representation of the steps occurring at the active site of 
MsrA to form the sulfenic acid intermediate. (Picture taken from Boschi-Muller, 
2014) 
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1.6 Endoplasmic reticulum (ER) 
The endoplasmic reticulum (ER) is the major site of protein synthesis and 
protein-folding. It comprises of molecular chaperones which help the proteins to 
fold, as well as, a well distinguished set of sensory proteins that helps to detect mis-
folded or unfolded proteins. Due to the presence of high concentrations of unfolded 
proteins and nascent polypetides in the ER matrix, it is also a major site for the 
reactive oxygen species to target such unfolded and nascent polypetides.  
The accumulation of unfolded or misfolded proteins within the ER lumen leads 
to greater aggregation of intracellular ROS, thereby, enhancing the magnitude of the 
ER oxidative stress. Consecutively, different repair mechanisms are present within 
the ER which help to prevent protein misfolding due to ROS induced oxidative stress 
(Liu and Kaufman, 2003, Zhang and Kaufman, 2008, Malhotra and Kaufman, 2007). 
Since, the MsrB3A is localised within the ER of the cells in humans, therefore, this 
thesis aims to study the structure and function of MsrB3A as the primary subject. 
Another interesting feature which was found in the ER was the absence of MsrA 
protein or its isoform, suggesting that either MsrB3A is somehow able to reduce both 
the diastereomers of methionine sulfoxide or an epimerase enzyme is present within 
the ER which helps in switching of the stereoisomer forms from S- to R-form, 
thereby, helping to reduce the methionine sulfoxide to methionine.  
 
1.7 Objectives of the thesis 
 
The first objective of the thesis was to clone the mature MsrB3A gene in to 
recombinant Escherichia coli cells and successfully over-express the recombinant 
MsrB3A protein to gain sufficient quantity of protein for structural and functional 
studies.  
As discussed earlier in Table 1.1, there is no available structure for MsrB3A. 
Hence, on one hand, this thesis made an attempt to determine the structure of 
MsrB3A protein. The knowledge gained from the structural experiments might then 
be used for elucidating the events occuring at the active site of the protein, as well 
as, to find potential substrates within the immortalised human cell lines which 
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would provide more detailed outlook into human disorders like Alzheimer’s disease 
and Parkinson’s disease. 
Consecutively, the another aim of this thesis was to establish whether the 
126th position cysteine in the MsrB3A protein sequence is an active site cysteine 
responsible for the protein function. This was based on the hypothesis that the 126th 
position cysteine present in the MsrB3A protein sequence is a resolving cysteine 
residue involved in the protein function as it coincided with the  conserved region 
containing selenocysteine of the MsrB1 (or SelR) obtained in the multiple sequence 
alignment (Fig. 3.1) towards the N-terminal of the protein chain. From the 
literature, it is known that selenocysteine is present at the active site and is 
responsible for the protein function. Hence, it could be assumed that the 126th 
position cysteine residue in the MsrB3A portein sequence might be a resolving 
cysteine residue responsible for the protein function. Therefore, using site directed 
mutagensis the 126th position cysteine residue was substituted for alanine to create 
a non-functional mutant MsrB3A protein and protein function was determined using 
gel shift assay and a HPLC assay, respectively, to test the hypothesis. 
 
1.8 Outline of the thesis 
The above objectives were addressed in the results chapters which are being 
divided between chapters 3 to 6 in an orderly manner. Chapter 2 mainly deals with 
the various techniques that was used in the experiments to determine the results 
and meet the objectives. 
In the first half of chapter 3, we aim for the successful expression, extraction 
and purification of the recombinant MsrB3A protein in sufficient quantity to be used 
for structural and functional studies. In the next part of chapter 3, results related 
with the determination of structure of MsrB3A protein were discussed in detail. 
Chapter 4 was based on the creation of 126th position cysteine mutant protein 
(C126A MsrB3A mutant), using site directed mutagenesis. While chapters 5 and 6 
deal with the functional assay for MsrB3A protein using a gel shift assay and a HPLC 
assay, respectively. 
The results chapters (chapter 3 to 6) are followed by an conclusions chapter 
which mainly summarises the entire thesis and also highlights the potential areas of 
further research which is required to gain more detailed knowledge about MsrB3A 
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protein, as well as, their role in maintainance of antioxidant defence and regulation 
of protein function within the endoplasmic reticulum.   
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Chapter 2: Materials and methods 
2.1   Expression of human MsrB3A in E. coli BL21 (DE 3) Star pLysS cells 
 
The human MsrB3A gene linked with N-terminus 6X His-tag was cloned into a 
pET21a (+) plasmid. The construct was transformed in E. coli BL21 (DE 3) Star pLysS 
cells for expressing the recombinant MsrB3A protein. The transformed E. coli cells 
were then grown in selective Luria Broth (LB) media (Appendix) containing 0.1 
mg/ml ampicillin, until the O.D.600 reached 0.5. The expression of the recombinant 
MsrB3A protein was then induced by 0.5 mM IPTG, supplemented with 0.5 mM ZnCl2. 
The induction was done for 3 hours at 37°C. The expression was analysed on 15% 
SDS-PAGE gel. Later, the expression was further increased by growing the 
transformed E. coli cells in selective terrific broth (TB) media containing 0.1 mg/ml 
ampicillin and then induced for protein expression using 0.25 mM IPTG, 
supplemented with 0.5 mM ZnCl2 at 18°C. 
After protein expression, the cell culture was centrifuged at 3,836xg for 15 
minutes using Beckman JA 14 Fixed Angle Rotor and Beckman Coulter J2-HS 
centrifuge. The supernatant was disposed aseptically and the cell pellet was re-
suspended in 20 ml of 50 mM HEPES 150 mM NaCl and 5 mM Imidazole, pH 7.5 
buffer. 
 
2.2.1 Protein extraction and purification 
 
To check for expression on a bench scale, the cell culture after induction of 
protein expression was treated with 1X BugBuster™ Protein Extraction Reagent from 
Novagen, as per the procedure provided within the kit, to lyse the recombinant cells 
to release the intracellular proteins. The cell suspension was then centrifuged at 
16,162Xg in a micro-centrifuge and the samples were analysed on 15% SDS-PAGE gel. 
The clarified solution (supernatant) was subsequently applied to TALON® 
SuperFlow™ Affinity Resin from GE Healthcare Life Sciences for the purification of 
the 6X His-tagged MsrB3A proteins which binds with the Co2+ ions present in the 
resin. The purified samples were then collected and analysed on 15% SDS-PAGE gel 
to check for purity.     
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The resuspended cells from scaled-up cell cultures were lysed using a French 
Press at 950 psi pressure. After cell lysis, the cell suspension was centrifuged at 
11,424xg for 20 minutes using Beckman JA 17 Fixed Angle Rotor and Beckman 
Coulter J2-HS centrifuge, following which the supernatant was collected. The 
supernatant was then filtered using a 0.45 µm Minisart® High Flow syringe filter from 
Sartorius before being applied to Fast protein liquid chromatography (FPLC). 
The following purification steps were involved using the FPLC -  
a. Immobilised metal affinity chromatography (IMAC): - The filtered supernatant was 
applied to a 5 ml HisTrap™ HP column (from GE Healthcare) that was pre-
equilibrated with 50 mM HEPES 150 mM NaCl and 5 mM Imidazole, pH 7.5 buffer 
(binding buffer). The column was then washed with 50 ml (10 column volumes or 10 
C.V.) of the binding buffer to enable binding of the His-tagged proteins while the 
non-binding contaminants flow out of the column. Elution for His-tagged protein was 
carried out with increase in gradient of elution buffer (50 mM HEPES 150 mM NaCl 
and 500 mM Imidazole, pH 7.5) from 0 to 100%, over 50 ml (10 C.V.). The elution 
buffer was further applied for 15 ml (3 C.V.) at 100% concentration to completely 
elute out the proteins. The elution samples were then collected in accordance to 
their absorption peaks at 280 nm and analysed by SDS-PAGE gel electrophoresis. 
 
b. Desalting: - The IMAC purified samples was then applied to HiPrep™ 26/10 Desalting 
column to filter out the salt and imidazole present in the samples with a buffer 
containing 50mM HEPES, pH 8.0 buffer. 
 
c. Ion exchange chromatography: - The desalted samples were applied to 2X 5 ml Hi-
Trap™ Q HP columns which were pre-equilibrated with 50 mM HEPES, pH 8.0 (binding 
buffer) to purify the protein based on their charge difference. The samples in the 
column were then washed with 20 ml (2 C.V. each) of binding buffer (50 mM HEPES, 
pH 8.0) for the proteins to bind. The proteins were eluted out of the column by 
applying a 50 ml (5 C.V. each) linear concentration gradient for elution buffer (50 
mM HEPES and 500 mM NaCl, pH 8.0) by varying the concentration of elution buffer 
from 0 to 100%. The 100% concentration of elution buffer was maintained for further 
10 ml (1 C.V. each) to completely elute out any remaining protein. The elution 
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samples were then collected in accordance to their absorption peaks at 280 nm and 
analysed by SDS-PAGE gel electrophoresis.   
 
d. Gel filtration chromatography: - In this step, the ion exchange purified samples were 
first collected and concentrated to 1ml as described below in section 2.2.2. After 
concentration, the samples were purified based on their molecular size using 
Superdex 200 10/300 GL gel filtration chromatography column. The concentrated 
sample was applied to the column and subsequently eluted out using 1 C.V. of 20 
mM HEPES and 150 mM NaCl, pH 7.5 buffer (elution buffer). The purified samples in 
which the peaks were observed at 280 nm UV absorbance were analysed by SDS-
PAGE gel electrophoresis.   
 
2.2.2 Protein concentration and quantification 
The purified protein was concentrated using a Sartorius VivaSpin Turbo 15 
Concentrator (MWCO= 10,000 Da), at 3,000xg until the desired volume. After 
concentration, the protein solution was collected in an Eppendorf tube.  
Absorbance of the concentrated protein solution was measured at 280 nm 
with the help of L-Vis plate and the SpectroStar Nano UV Spectrometer.  The protein 
concentration was quantified using the Beer- Lambert’s law. 
The extinction coefficient (ɛ) for MsrB3A and SurA protein was calculated 
using the ProtParam bioinformatic tool by providing the amino acid sequence for the 
respective proteins as input.  
    ɛ → Extinction coefficient at 280 nm (M-1cm-1) = 13,325 M-1cm-1 (for MsrB3A) 
                                                                      = 29,450 M-1cm-1 (for SurA) 
After protein quantification, the solution was aliquoted and flash frozen using 
liquid nitrogen. 
2.3.1 Spectroscopic techniques: CD spectroscopy 
The concentrated MsrB3A protein aliquots were diluted to a concentration of 
1 mg/ml using 20 mM HEPES 150mM NaCl, pH 7.5 buffer. The samples were then 
examined at near and far UV ranges to determine the secondary structure and 
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folding under different conditions (native, in the presence of 1 mM TCEP for 
reducing conditions and 1 mM EDTA to strip off any metal ions linked to the MsrB3A 
protein). 
2.3.2 Spectroscopic techniques: NMR spectroscopy 
15N labelled MsrB3A was expressed by growing the recombinant E. coli cells in 
M9 liquid medium (Appendix) containing 15NH4Cl salt. The recombinant MsrB3A protein 
was extracted, purified and concentrated as per the methods described in section 
2.2.1 and 2.2.2. 
NMR spectra was acquired from 600 µl sample of 0.372 mM MsrB3A protein in 50 
mM sodium phosphate and 100 mM NaCl buffer at pH 6.5, containing 10% D2O. The 
sample was added to a clean NMR tube (Wilmad 535-pp7) using an NMR pipette for 
measuring the NMR spectra. The NMR spectra was measured at 298 K using 600 MHz 
Bruker Avance III HD NMR spectrometer equipped with TCI cryo-probe. The 15N/1H 
HSQC sequence spectra was obtained using the Fast HSQC (FHSQC) pulse program 
(Mori et al., 1995). The 15N/1H HSQC spectra data was collected for 5 minutes.  
2.3.3 Protein crystallisation 
Purified protein samples at 40 mg/ml and 20 mg/ml were added to four 96 well 
crystallisation screening plates- Morpheus® HT-96, Structure Screen 1 & 2 HT-96, 
JCSG-plusTM HT-96, and PACT premier™ designed by Molecular Dynamics in sitting 
drop configuration using the robotic arm (Cartesian Robot). The plates were then 
sealed using clean transparent plastic and were incubated at 16 ˚C for 3 months. The 
plates were observed every week under a microscope to check for any crystal growth 
in the 3 months of incubation period. 
Optimisation of crystallisation conditions was made by varying the salt 
concentration in the crystallisation buffer over different pH range in a 24 well 
crystallisation condition screening plate. Again, the crystallisation plates were sealed 
using clean transparent plastic and incubated at 16 ˚C for 3 months. 
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Table 2.1: Nested PCR reaction mixture.  
2.4.1 Site directed mutagenesis: conversion of 126th position cysteine to alanine 
Synthetic DNA primers- Forward Primer (5’- 
GACCGGTAAACGCTACGCCATCAATAGCGCGGCC-3’) and Reverse Primer (5'-
GGCCGCGCTATTGATGGCGTAGCGTTTACCGGTC-3') incorporating the mutation of 
cysteine to alanine (TGC→GCC) in the 126th position of the amino acid sequence of 
MsrB3A were designed and ordered from Agilent Technologies. The primers were then 
amplified using pET21a (+) plasmid containing the mature gene sequence of the 
MsrB3A wild-type DNA as the parental DNA strand, ACCUZYME™ DNA polymerase from 
Bioline Reagents Ltd. and nested-PCR for 25 cycles. The PCR mixture and nested PCR 
cycle parameters used are represented by Table 2.1 and 2.2, respectively.  
 
 
 
Constituents 
 
Control (μl) 
 
 
Sample 
(μl) 
 
10X AccuBuffer 5 5 
ACCUZYME™ DNA polymerase (2.5 U/μl) 1 1 
25 mM MgCl2  2 2 
Primers (conc.= 25 ng/μl)  
0 
 
5 Forward primer 
Reverse primer 
10 mM dNTP mix (dATP, dGTP, dCTP, and dTTP) 1 1 
DMSO 1 1 
dsDNA template (conc.= 50 ng/μl) 1 1 
ddH2O 39 34 
Total reaction volume (μl) 50 
 
(Note- The DNA polymerase enzyme is added at the end just before starting the PCR 
reaction.) 
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Table 2.1: Nested PCR reaction parameters.  
 
The resulting amplified PCR product was then treated with Dpn I restriction 
endonuclease to digest the methylated parental DNA strand. The Dpn I digested 
product was then transformed into E. coli XL1 Blue super-competent cells. The 
transformed cells were then grown in selective LB Agar media containing 0.1 mg/ml 
ampicillin for 24 hours at 37 ˚C.  
Colonies were selected from the culture plate and marked. The selected 
colonies were then grown over-night in selective LB broth containing 0.1 mg/ml 
ampicillin at 37 ˚C. The plasmid DNA was then isolated from the over-night cultures 
using alkaline lysis method for DNA purification. The DNA purity and concentration 
was measured using L-Vis plate, the SpectroStar Nano UV Spectrometer and MARS Data 
Analysis software. Cysteine to alanine (TGC→GCC) mutation was verified by DNA 
sequencing services provided by GATC Biotech.  
    
2.5.1 Gel shift assay 
The transformed E. coli BL 21 (DE3) cells harbouring the pKD 11 plasmid 
containing the SurA gene linked with 6X-His-tag at the C-terminus (obtained by 
request from Prof. J.F. Collet) was first grown in selective terrific broth media 
containing 0.1 mg/ml kanamycin up to an O.D.600 of 0.5. Protein over-expression was 
induced using 0.5 mM IPTG and was carried out for 16 hours at 20°C. The SurA 
protein was then purified and concentrated similarly to the steps involved in MsrB3A 
purification as described in section 2.2.1 and 2.2.2.  
 
Step 
 
 
Temperature (°C) 
 
Time (mins.) 
 
Cycles 
Melting 95 5 1 
Melting 95 0.5  
30 Annealing 60 0.5 
Elongation 72 1 
Elongation 72 10 1 
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An aliquot of the purified and concentrated SurA was first diluted to 200 µM 
and was then oxidised in-vitro by incubating the protein with 100 mM H2O2 at 30°C 
for 3 hours (Gennaris et al., 2015) in 20 mM HEPES and 150 mM NaCl, pH 7.5 buffer. 
The H2O2 was then removed from the solution by gel filtration chromatography using 
a pre-equilibrated 5 ml HiTrap™ Desalting column and AKTAPurifier FPLC system. 
Equilibration of the column was done using 20 mM HEPES and 150 mM NaCl, pH 7.5 
buffer. The purified samples were pooled together, concentrated and quantified as 
described in section 2.2.2 
In-vitro repair of oxidised SurA was done by incubating 20 µM SurA with 
different concentrations of MsrB3A at 37°C for one hour, in the presence and 
absence of 10 mM DTT. Following the treatment with MsrB3A the samples were 
analysed on 10% SDS-PAGE gels to check the mobility of SurA. 
2.5.2 High pressure liquid chromatography (HPLC) assay 
The HPLC assay was done according to the procedure described by (Kumar et 
al., 2002). 0.2 mg/ml MsrB3A (wild-type) or C126A MsrB3A mutant protein was mixed 
with 0.5 mM dabsylated methionine sulfoxide and added to 50 mM NaCl, 20 mM DTT 
and 20 mM Tris, pH 7.0 buffer in a total sample volume of 0.2 ml. The reaction mix 
was incubated at 30°C for 5, 10, 20 and 30 minutes and then quenched using 0.5% 
SDS. 
The reaction products were then separated based on their hydrophobicity 
using reverse phase chromatography (RPC) column (Sephasil peptide C18 5µm ST 
4.6/250 column) and ÄKTAmicro™ Chromatography system. The reaction mix was 
then applied to the column which was pre-equilibrated with 5 C.V. of 100 mM 
sodium acetate and 30% acetonitrile, pH 6.0 buffer (binding buffer) and 
subsequently washed with 1 C.V. of binding buffer to enable binding of reaction 
products. The reaction products were separated from each other by the help of a 
concentration gradient over 2 C.V. of 100 mM sodium acetate and 70% acetonitrile, 
pH 6.0 buffer (elution buffer) from 0 to 100% of the elution buffer. The 100% 
concentration of elution buffer was maintained for further 1 C.V. to completely 
elute out any remaining products. Sample mix containing only dabsylated 
methionine and dabsylated methionine sulfoxide respectively, were used as 
reference to determine the retention time.   
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Chapter 3: MsrB3A: Protein expression, 
purification and structural studies. 
3.1 Introduction 
Methionine sulfoxide reductases occur in two major forms- MsrA and MsrB, 
which catalyses the reduction of methionine sulfoxide to methionine, thereby, 
acting as antioxidants within the cell in response to oxidative stress. MsrA catalyses 
reduction of methionine-S-sulfoxide while MsrB catalyses the reduction of 
methionine-R-sulfoxide.  
The structure and function of MsrA is widely known and well-characterised 
due to the studies performed on it (Brot et al., 1981, Tête-Favier et al., 2000, 
Vougier et al., 2003, Hansel et al., 2002, Antoine et al., 2003, Yermolaieva et al., 
2004). Although MsrB proteins have been identified quite recently, not much is 
known about them. However, MsrB has been reported to occur in various organisms 
from bacteria to mammals in different forms localised to specific organelles 
(Grimaud et al., 2001, Jung et al., 2002, Kryukov et al., 2002, Kumar et al., 2002, 
Olry et al., 2002, Etienne et al., 2003, Spector et al., 2003).  
In mammals, only a single gene encoding for the MsrA protein is present in 
mitochondria, cytosol and nucleus (Kim and Gladyshev, 2005b, Kim et al., 2010, 
Vougier et al., 2003). In contrast to MsrA, MsrB  is encoded by three different genes 
(B1-B3) and targeted to different cellular compartments (Kim and Gladyshev, 
2004b). MsrB1 is present in the nucleus and cytosol, while MsrB2 is targeted to the 
mitochondria. MsrB3 is found within the endoplasmic reticulum of most mammals. 
But in humans, an isoform of MsrB3 is also targeted to the mitochondria which is a 
unique feature that has not been observed in any other mammal. 
As stated in the previous paragraph, MsrB3 occurs in two different isoforms in 
humans, namely, MsrB3A and MsrB3B. This is due to the alternative splicing of the 
first exon, which results in contrasting N-terminal signal peptides. Although recent 
studies conducted on mice  have found that the mouse MsrB3 contains consecutive 
ER and mitochondrial targeting signals in the N-terminus, the MsrB3 protein is only 
localised within the ER (Kim and Gladyshev, 2004a). Another reason for the presence 
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of two isoforms of MsrB in the mitochondria in humans could be due to the inhibition 
of MsrB2 at high substrate concentrations, while MsrB3B can then help reduce 
methionine-R-sulfoxide at concentrations higher than 1 mM (Kim and Gladyshev, 
2004b). 
Although, both MsrA and MsrB perform the same function of methionine 
sulfoxide reduction to methionine, they both differ from each other with respect to 
their mode of action and arrangement of the amino acids at the active site of the 
protein. Previous studies conducted on MsrA has helped to understand and establish 
the mode of action of MsrA to reduce methionine-S-sulfoxide to methionine 
(Dokainish and Gauld, 2013). But the same cannot be said for MsrB. Although the 
mode of function for MsrB has been found for some human pathogens such as 
Neisseria gonorrhoeae (Robinet et al., 2011), by sequence analysis (Fig. 3.1) it has 
been observed that the MsrB sequences in various organisms differ from each other, 
hence differing in their mode of action, arrangement of amino acids at their active 
site, substrate binding capacity and localisation to specific regions of the cell. For 
example, MsrB1 in eukaryotic cells possess a seleno-cysteine (represented by codon 
‘U’, in the amino acid sequence) in its active site that helps in the reduction of 
methionine-R-sulfoxide (Kim and Gladyshev, 2004b, Kim and Gladyshev, 2007). But 
MsrB2 and MsrB3 do not contain any specialised amino acid but only cysteine residue 
at the active site to reduce methionine-R-sulfoxide (Kim and Gladyshev, 2005a), as 
observed in the sequence alignment. It is also noted that all MsrB have Zn2+ as co-
factors which are strongly bound. From sequence analysis it is observed that all MsrB 
has two Zn2+ binding sites in the form of -CXXC- motifs (Kumar et al., 2002), as a 
characteristic feature. 
As stated earlier, the structure and function of MsrA have been well defined 
throughout literature for most organisms, owing to the widespread study in the past 
two decades. But the same cannot be said for MsrB. Although, MsrB structures have 
been found for some micro-organisms, particularly human pathogens like N. 
gonorrhoeae, N. meningitides (Ranaivoson et al., 2009, Lowther et al., 2002) etc., 
they lack homology to the mammalian enzymes. In case of mammals, only the 
structure for mouse MsrB1 has been determined (Aachmann et al., 2010). Though, 
recently the crystal structure of human MsrB1 (PDB id- 3MAO) and structure of 
mouse MsrB2 (NMR Ensemble; PDB id- 2L1U (unpublished data by Aachmann et al., 
Page | 38  
 
2010)) has been determined. The structure of MsrB3 protein remains unknown. 
Hence, we shall also try to focus on finding the structure for human MsrB3A. Since 
MsrB3A has been recently identified, its mode of action and structure are still 
unknown. Hence, our primary aim is to express the MsrB3A gene within recombinant 
E. coli to generate optimal quantities of MsrB3A protein, which can then be utilised 
to study the structure and mode of action. Secondly, we shall conduct structural 
experiments using circular dichroism (CD) spectroscopy, nuclear magnetic resonance 
(NMR) spectroscopy and X-ray crystallography to determine the structure of MsrB3A. 
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Figure 3.1:  Multiple sequence alignment of amino acid sequences of different MsrB variants from 
various organisms.  
Alignment of full length sequences of MsrB proteins from humans {GenBank Accession Number- 
EAW97151.1 (MsrB3), AAH18030.1 (MsrB2), NP_057416.1 (MsrB1)}; mouse {GenBank Accession Number- 
EDL24407.1 (MsrB3), EDL08114.1 (MsrB2), NP_001333597.1 (MsrB1); Drosophila melanogaster MsrB 
(GenBank Accession Number- Q8INK9.3); Escherichia coli MsrB (GenBank Accession Number- EMZ45312.1); 
Methanobacterium congolense MsrB (GenBank Accession Number- SCG84896.1); Halobacterium hubeiense 
MsrB (GenBank Accession Number- CQH58376.1). The amino acid residues coloured in blue have the least 
conserved residue domains, while the amino acid residues coloured in red are the most conserved residue 
regions. The highlighted region represents the Zn2+ binding motif region -CXXC- which remains conserved 
throughout the different sequences shown. The conserved cysteine region marked by the red rounded 
edged rectangle represents the functional cysteine as described by Kumar, 2002. (Note- Both MsrB3A and 
MsrB3B have identical protein sequences, except that MsrB3B has an extension at its N-terminal generated 
by alternative splicing.)  
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3.2 Results 
3.2.1 Protein expression, extraction and purification 
 
To study human MsrB3A in detail, the human MsrB3A gene lacking the N-
terminal signal peptide for the endoplasmic reticulum was replaced by 6X His-tag 
sequence and cloned into pET 21a (+) plasmid. The construct was used for 
transformation in E. coli BL 21 (DE 3) Star pLysS cells to express the recombinant 
MsrB3A protein, as stated in section 2.1. The first step was to check whether the 
protein could be expressed on a bench scale using the recombinant bacteria. The 
transformed E. coli cells were grown in selective LB broth media and protein 
expression was induced using IPTG. Protein expression was then visualised on 15% 
SDS-PAGE gel (Fig. 3.2). Lanes 1 and 2 represent the cell samples before and after 
protein induction by IPTG. As we can observe from lane 1 that the recombinant E. 
coli cells have a band in between the 17 and 22 KDa region. This could be due to 
“leaky expression” of the recombinant MsrB3A protein as recombinant E. coli BL 21 
(DE 3) Star cells are known to have some basal level expression of the gene of 
interest as stated by the vendor. Another factor contributing to the leaky expression 
of recombinant MsrB3A protein is the absence of chloramphenicol in the culture 
media which was essential for the activation of pLysS plasmid to produce the T7 
lysozyme which then reduces the basal level or leaky expression of the gene of 
interest in uninduced cells. Hence, from lane 2 we observe a slightly thicker band 
indicating there is a small increase in the quantity of protein expressed after the 
induction of protein expression by IPTG, which might be due to the expression of 
MsrB3A. Another evidence of the leaky expression would be the expression of the 
C126A MsrB3A mutant protein which is discussed in detail in Chapter 4. Up on 
comparison of the elution curves of gel filtration chromatography in Fig. 3.7, 3.13 
and 4.6, it can be clearly observed that the peak always lie in the same region. 
Following protein expression, the cell culture was treated with BugBuster™ 
10X Protein Extraction reagent from Novagen to extract the recombinant MsrB3A 
protein. The extraction sample, pellet and supernatant (clarified solution) were 
then analysed on 15% SDS-PAGE gel (Fig. 3.3). Lane E represents the extraction cell 
Page | 41  
 
culture sample after treatment with BugBuster™ 10X Protein Extraction reagent. 
Lanes P and Sn represents the pellet and supernatant respectively. Lane P has a 
faint band, while lane Sn has a thick band when compared with lane E. This suggests 
that the expressed recombinant MsrB3A protein is soluble.  
Subsequently, the clarified solution (supernatant) obtained from the protein 
extraction was applied to TALON® Superflow™ Affinity Resin which contains Co2+ ions 
conjugated to the beads, for purification of the recombinant MsrB3A protein. The 6X 
His-tag present in the protein construct binds strongly with the metal ion present in 
the bead, hence, separating the recombinant protein from the unwanted proteins. 
Following purification, the purified samples obtained were analysed on 15% SDS-
PAGE gel as shown in Fig. 3.4. Lane Sn represents the clarified solution 
(supernatant), lanes FT and W represents the 1st and 2nd washes respectively. Lane 
El represents the elution.  
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Figure 3.2:  SDS-PAGE gel analysis of 
MsrB3A protein expression in Luria-Bertani 
(LB) broth media.  
Lane M represents the Blue pre-stained 
Protein Standard as reference of protein 
size. Lane 1 represents the sample from cell 
culture just before induction of protein 
expression using IPTG, while lane 2 
represents the sample from cell culture after 
3 hours of induction of protein expression 
using IPTG.  
Figure 3.3:  SDS-PAGE gel analysis of MsrB3A 
protein extraction using BugBuster™ Protein 
Extraction Reagent.  
Lane M represents the Blue pre-stained Protein 
Standard as reference of protein size.Lanes P and 
Sn represent the pellet and supernatant samples 
obtained after the cell extract was centrifuged 
at 16,162xg in a micro-centrifuge, respectively. 
Lane E represents extraction sample after cell 
culture was treated with 1X BugBuster™ Protein 
Extraction Reagent. 
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Figure 3.4:  SDS-PAGE gel analysis of MsrB3A protein purification using 
Talon® Superflow™ Affinity Resin.  
Lane M represents the Blue pre-stained Protein Standard as reference of protein 
size.Lane Sn represents the non-purified supernatant (clarified solution) sample 
which is applied to the Talon® Superflow™ Affinity Resin. Lane FT and W 
represent the sample from the flow-through or 1st wash and 2nd wash of the 
resin using 50 mM HEPES 150mM NaCl, pH 7.5 (wash) buffer. Lane El represents 
the purified MsrB3A protein eluted out when 50 mM HEPES 150 mM NaCl 500 mM 
imidazole, pH 7.5 (elution) buffer was applied to the resin. 
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A clear, single and distinct band was obtained in the elution. This meant that 
the protein could be purified easily using immobilised metal affinity chromatography 
(IMAC). We can also notice in figure 8 that MsrB3A is also present in lanes FT and W. 
This could be due to the saturation of the beads which can bind with the protein 
suggesting that the concentration of protein was far greater than the quantity of 
binding sites available.      
Hence, after successfully establishing that the recombinant MsrB3A can be 
expressed on bench scale, the protein expression was scaled up by growing the 
recombinant E. coli in 2 l of selective LB broth media and then inducing protein 
expression using IPTG.  Cell lysis was carried out using a French Press, as discussed 
in section 2.1. The cell lysate was then analysed using 15% SDS-PAGE gel (Fig. 3.5).  
As we can observe in lane P, there is still some amount of MsrB3A present in the 
pellet, indicating that the procedure was not efficient and a fraction of the cells 
was not lysed. However, the supernatant obtained after centrifugation of the cell 
lysate was first filtered as discussed in Section 2.2.1, before applying to 5 ml 
HisTrap™ HP column for IMAC chromatography using the AKTA FPLC system for 
purification. After purification using IMAC chromatography, the eluted proteins were 
analysed on a 15% SDS-PAGE gel (Fig. 3.6). As we can observe, the samples in lane 5 
to 7 contains considerable amount of the recombinant MsrB3A. Yet small quantities 
of contaminant proteins were still present in the samples. Hence, to get a better 
purification the samples were pooled together and concentrated as discussed in 
section 2.2.2. Following concentration, the sample was applied to Superdex 200 
10/300 GL gel filtration chromatography column for further purification based on 
molecular size difference (Fig. 3.7). The eluted samples obtained after purification, 
were analysed on a 15% SDS-PAGE gel to check for purity. Typical concentrations 
achieved after protein expression in LB broth media and purification ranged 
between 0.5 to 0.6 mg/l of culture. Although, we could successfully isolate the 
recombinant MsrB3A, the quantity of protein required was not sufficient to perform 
structural studies and analysis of protein functions. Hence, purifying the 
recombinant protein on multiple occasions might result in unwanted variations in 
the results obtained on analysis. It is better to get a standard result from a single 
purified sample.   
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Figure 3.5:  SDS-PAGE gel analysis of MsrB3A protein extraction using 
French Press.  
Lane M represents the Blue pre-stained Protein Standard as reference of 
protein size.Lane E represents extraction sample after cell lysis using the 
French Press. Lanes P and Sn represents the pellet and supernatant 
samples obtained after the cell extract was centrifuged at 3,836Xg for 15 
minutes using Beckman JA 14 Fixed Angle rotor and Beckman-Coulter J2-
HS cold centrifuge, respectively. 
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Figure 3.6:  Immobilised metal affinity chromatography (IMAC) purification of His-tagged MsrB3A 
protein.  
A. The graph represents a typical FPLC Chromatogram obtained using a 5 ml HisTrap™ HP affinity column 
for purifying the 6X His-tagged MsrB3A protein. The bound protein was eluted by using a 500 mM 
Imidazole concentration gradient represented by the orange curve. 
B. SDS-PAGE gel analysis of the samples of the purified fractions collected from the peaks obtained as 
shown in A. Lane M represents the Blue Protein Standard used as reference. Lane FT represents the 
sample from the flow through elution peak, while lanes 1 to 7 represent the fractions collected from 
the MsrB3A elution peak in successive order and is represented in the graph by an arrow. 
A
. 
B
. 
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Figure 3.7: Gel filtration chromatography purification of MsrB3A protein.  
A. The graph represents a typical FPLC Chromatogram obtained using a Superdex 200 10/300 GL gel 
filtration chromatography column for purifying the MsrB3A protein based on the principle of 
molecular size exclusion. 
B. SDS-PAGE gel analysis of the samples of the purified fractions collected from the peaks obtained as 
shown in the graph. Lane M represents the Blue Protein Standard used as reference. Lanes 1 and 2 
represent the samples from the fractions collected from the MsrB3A elution peak in successive 
order and is represented in graph by an arrow. 
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 To generate sufficient quantity of recombinant MsrB3A protein for further 
experiment, the recombinant E. coli cells were grown in selective terrific broth (TB) 
media, as described in section 2.1. Although, the recombinant E. coli cells were first 
grown at 37°C like in LB media, once the OD600 of 0.5 was reached, the protein 
induction was carried out at 18°C using IPTG. The primary reason for this was to 
have a slower growth rate while keeping the cells in their logarithmic phase of 
growth. Protein expression was checked by analysing the samples on a 15% SDS-PAGE 
gel (Fig. 3.8). As we can observe from the thick band in lane 2, the quantity of 
recombinant protein increased after induction of protein expression using IPTG with 
respect to lane 1 (before protein induction). The cells were then lysed using French 
Press for protein extraction and the cell lysates were analysed using 15% SDS-PAGE 
gel (Fig.3.9).  
In the same way as the earlier purification, the clarified solution (filtered 
supernatant) was applied to the 5 ml HisTrap™ HP column for IMAC chromatography 
using the AKTA FPLC system. As we can observe from the elution profile in Fig. 3.10, 
the quantity of recombinant protein purified was almost three times more than the 
amount produced when LB media was used. The only drawback of the increase in 
concentration of recombinant protein was the increase in concentration of 
contaminant proteins. Hence, we removed the unwanted proteins based on surface 
charge difference using ion exchange chromatography (Fig. 3.12). As the elution 
buffer for IMAC chromatography consisted of 150mM NaCl and imidazole, we first 
removed the salt from the samples, using the HiPrep™ 26/10 Desalting column and 
50 mM HEPES pH 8.0 buffer, as discussed in section 2.2.1. This was done to avoid 
interference from the salt molecules with the resin of the ion exchange column. Fig. 
3.11 illustrates the elution profile of desalting step. The desalted samples were then 
applied to the 5 ml Hi-Trap™ Q HP columns to purify the recombinant MsrB3A protein 
from the contaminants based on the surface charge difference (Fig. 3.12). The 
fractions collected after ion exchange chromatography were then concentrated up 
to 1 ml as described in section 2.2.2. The concentrated sample was then applied to 
the Superdex 200 10/300 GL gel filtration chromatography column to obtain 
recombinant MsrB3A protein with high degree of purity (Fig. 3.13, panel B). As we 
can also observe in panel A, there are two elution peaks which occur adjacent with 
each other. This could be due to formation of dimers which may result in the 
formation of a separate peak.  
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Figure 3.8:  SDS-PAGE gel analysis of MsrB3A protein expression in terrific broth (TB) media.  
Lanes 1 and 2 represent the samples from cell culture just before and after over-night induction of 
protein expression using IPTG. 
         
 
Figure 3.9:  Protein extraction of MsrB3A using French Press. 
Lane E represents extraction sample after cell lysis using French Press. Lanes P and Sn represent the 
pellet and supernatant samples obtained after the cell extract was centrifuged at 3,836xg for 15 
minutes using Beckman JA 14 Fixed Angle rotor and Beckman Coulter J2-HS cold centrifuge, 
respectively. 
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Figure 3.10:  Immobilised metal affinity chromatography (IMAC) purification of 6XHis-tagged MsrB3A 
protein.  
A. Typical FPLC chromatogram obtained by using a 5 ml HisTrap™ HP affinity column. The bound protein 
was eluted using a 500 mM Imidazole concentration gradient represented by the orange curve. 
B. SDS-PAGE gel analysis of the samples of the purified fractions collected from the peaks obtained as 
shown in A. Lane 1 represents the sample from the flow through elution peak, while lanes 2 to 8 
represent the samples from the fractions collected from the MsrB3A elution peak in successive order. 
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Figure 3.11:  Desalting of IMAC purified MsrB3A samples. 
The graph represents a typical FPLC Chromatogram obtained using HiPrep 26/10 Desalting 
column. As shown in the graph, the blue curve represents the absorbance of the protein sample 
at 280 nm and the salt represented by the conductivity curve in orange separated from the 
protein. 
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Figure 3.12:  Ion exchange chromatography purification of MsrB3A protein. 
A. Typical FPLC chromatogram obtained using two 5 ml Hi-Trap™ Q HP columns for purifying the MsrB3A 
protein based on the surface charge difference. The bound protein was eluted by using a 500 mM 
NaCl concentration gradient represented by the orange curve and increase of salt concentration is 
shown by the conductivity curve in red. 
 
B. SDS-PAGE gel analysis of the samples of the purified fractions collected from the peaks obtained as 
shown in graph. Lanes 1 to 7 represent the samples from the fractions collected from the MsrB3A 
elution peak in successive order and is represented in the graph by a double headed arrow. 
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Figure 3.13: Gel filtration chromatography purification of MsrB3A protein.  
A. Typical FPLC chromatogram obtained using a Superdex 200 10/300 GL gel filtration 
chromatography column for purifying the MsrB3A protein based on the principle of molecular size 
exclusion. 
 
B. SDS-PAGE gel analysis of the samples of the purified fractions collected from the peaks obtained 
as shown in the graph. Lanes 3 to 5 represent the samples from the fractions collected from the 
MsrB3A elution peak in successive order and is represented in graph by an arrow. 
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 A noticeable feature in all the purification steps is the presence of a distinct 
band between the 32 and 46 KDa marker bands, suggesting the formation of dimers 
by the recombinant MsrB3A protein. The net quantity of recombinant MsrB3A protein 
achieved after purification and concentration ranged between 4.5 to 6.0 mg/l of 
culture.  
 
3.2.2 Structural studies of recombinant MsrB3A 
  
  We approached determining the overall secondary structure of purified 
MsrB3A using circular dichroism (CD) spectroscopy, followed by an evaluation of the 
tertiary structure using NMR (nuclear magnetic resonance) spectroscopy and protein 
crystallography (X-ray crystallography) experiments as described below. 
 
3.2.2.1 CD spectroscopy 
Fig. 3.14 represents the CD spectral graphs of MsrB3A protein taken 
under different conditions, obtained at far UV (panel A) and near UV (panel B) 
respectively. As we can clearly observe from the figure that the recombinant 
MsrB3A protein has a folded structure owing to the strong CD signals giving 
rise to the curves obtained in the figure at both far and near UV range 
respectively.  
In both panels A and B, the native state of the MsrB3A protein is 
represented by the black curve. The blue curve represents MsrB3A protein 
after reduction using 1mM TCEP, as TCEP is a better reagent for sample 
analysis in CD spectroscopy (Getz et al., 1999).  The red curve represents the 
MsrB3A protein after treatment with 1mM EDTA. We use EDTA as a chelating 
agent to extract the Zn2+ ions present in MsrB3A protein, to study the effect 
of change in its secondary structure. 
Secondary structure estimation of MsrB3A protein was done for the 
native MsrB3A protein (black curve) using CONTIN/LL CD data analysis 
software (Sreerama and Woody, 2000, Provencher and Glöckner, 1981).  
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Figure 3.14:  CD Spectra of 1 mg/ml MsrB3A protein in its native state (black curve), 
when reduced with 1 mM TCEP (blue curve) and when treated with 2 mM EDTA (red 
curve) respectively, in 20 mM HEPES 150 mM NaCl, pH 7.5 buffer at 298 K.  
A. Panel showing the far UV CD spectra of MsrB3A protein.  
B. Panel showing the near UV CD spectra of MsrB3A protein. 
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Accordingly, it was predicted to have 35% β-sheeted structure, 11% α-helix, 
21% turns and 33% random secondary structures. This result is also in 
accordance with the structural composition predicted (Kryukov et al., 2002) 
for most MsrB proteins. 
In panel A, we observe that the reduced MsrB3A protein (blue curve) 
has a slightly broader and deeper peak between the 195 to 215 nm region in 
comparison to its native state for the far UV CD spectra, indicating partial 
unfolding of the protein structure.  
The same is also depicted in panel B for near UV spectra. We observe 
decrease in the positive peak between 250 to 260 nm and negative peak 
between 260 to 300 nm range, followed by the increase in the negative peak 
in the 300 to 325 nm region of the near UV region in comparison to the native 
MsrB3A protein (black curve). It can be said that EDTA treatment had no 
effect on the secondary structure of MsrB3A, as the red curve (EDTA treated 
MsrB3A protein) for the near UV region superimposed with the black curve. 
The slight discrepancies observed in the red curve could be the interference 
caused by EDTA.         
 
3.2.2.2 NMR spectroscopy 
Fig. 3.15 represents the two dimensional [1H, 15N]-HSQC spectra 
obtained for MsrB3A using 600 MHz Bruker Avance III HD NMR spectrometer at 
298 K. As we can observe in panel A, the contours are spread over a wide 
region, indicating that the MsrB3A protein has a folded structure. Each series 
of contour in the spectra represents a peak for the backbone H-N pair in each 
amino acid residue. 
Panel B represents the 2D [1H, 15N]-HSQC spectra obtained when 
MsrB3A was reduced (represented by blue contour) using 1 mM TCEP. The NMR 
spectra for the reduced MsrB3A was then compared with the native MsrB3A by 
super-imposing the 2D [1H, 15N]-HSQC spectra of native MsrB3A (represented 
by the red colour) over the NMR spectra of the reduced MsrB3A. Chemical 
shifts could be clearly observed, across various lengths, along with emergence 
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of new contour regions. This suggests a change in conformation possibly due 
to unfolding in the reduced MsrB3A protein. This support the results obtained 
by CD spectroscopy.     
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Figure 3.15:  NMR spectra of MsrB3A.  
Panels A represents the 600 MHz [1H, 15N]-HSQC spectra of 372 µM MsrB3A protein in 50 mM 
NaPO4 100 mM NaCl pH 6.5 buffer containing 10% D2O at 298 K, in its native state (represented 
as the blue contours).  
Panel B represents the 600 MHz [1H, 15N]-HSQC spectra of 372 µM MsrB3A protein after it was 
reduced by 1 mM TCEP in 50 mM NaPO4 100 mM NaCl pH 6.5 buffer containing 10% D2O at 298 
K (represented as the blue contours), superimposed by the 600 MHz [1H, 15N]-HSQC spectra of 
the native state of MsrB3A obtained earlier in panel A (represented by the red contours). 
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3.2.2.3 Protein crystallisation 
X-ray crystallography is another technique used for determining protein 
structure. Although it is the best technique to determine protein structure in 
atomic scale resolution, it is not always successful. The primary reason is the 
availability of protein crystals which are a must for the technique. Protein 
crystal formation is highly elusive on its own and requires a lot of trial and 
errors with different crystallisation conditions, thereby, making it a tedious 
and time-consuming process, when compared to NMR spectroscopy.   
With the aim of obtaining MsrB3A protein crystals, we set up 4X 96 well 
crystallisation screening plates made by Molecular Dynamics, as discussed 
earlier in section 2.3.3. In certain crystallisation screening plates hits were 
obtained for crystallisation conditions (Table 3.1). As observed, the 
crystallisation conditions of well E2 of screening plate JCSG-plus™ HT-96 had 
come up to the phase separation stage and the bubbles of the phase 
separation seemed to come together for crystal formation. But further 
incubation did not give any result. As for the well D1 of screening plate 
Morpheus® HT-96, tiny bulges occurring at regular intervals were observed, 
but up on being taken for analysis, they broke away, thereby, leading to 
failure of crystal structure determination. 
Since, phase separation was achieved in well E2 (Table 3.1), the 
crystallisation conditions were then optimised further to get crystals (Table 
3.2). As we can observe, the phase separation was too fast. Hence, crystals 
could not be formed and would result in formation of asymmetric amorphous 
solids. 
Therefore, to conclude the crystal trials did not yield protein crystals 
suitable for structural analysis. 
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Table 3.1: Crystallisation screening conditions for MsrB3A.  
Table 3.2: Optimisation of crystallisation condition for MsrB3A.  
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Discussions 
 
3.3.1 Protein expression, extraction and purification 
The MsrB3A gene was successfully cloned into the pET21a (+) plasmid and 
expressed in E. coli BL 21 (DE 3) Star pLysS cells to express the recombinant protein 
product. From all the extraction and purification processes that were observed for 
recombinant MsrB3A, it could be predicted that predominantly intact proteins were 
obtained, as only single peaks were detected in the elution curve in all the 
chromatographic steps. Although, slight shoulder was also present along with the 
single peaks, it would be amounted to formation of dimers that were seen in all the 
SDS-PAGE gels of the protein extraction and purification steps. This suggests that the 
stable recombinant protein product was obtained up on over-expression. 
As we can notice in the protein extraction in Fig. 3.3, minute amount of 
MsrB3A protein is still present in the pellet, even though a chemical process of 
extraction was used. A reason for this could be an improper mixing step with the 
chemical components of the BugBuster™ protein extraction, for which the step was 
not efficient. Another possible explanation could be the presence of minute amount 
of supernatant with the pellet, which could have resulted in the false positive 
result. As for the protein extraction using French Press (Fig. 3.5 and 3.9), similar 
condition is observed. A viable explanation for this inefficiency is the inadequate 
number of cell lysis cycles and use of lower driving pressure for which enough shear 
force could not be generated for completely lysing all the cells. Hence, the non-
lysed cells might be responsible for giving the false-positive result. A good way to 
lower the false positive result is to increase the number of lysis cycles to 6 to be 
more efficient.  
Since the recombinant MsrB3A protein was cloned with a 6X his-tag at its N-
terminal, IMAC chromatography was used effectively as the primary purification 
stage of the protein. As we can observe in Fig. 3.4, 3.6 and 3.10, we could purify the 
recombinant MsrB3A with high degree of purity on bench scale, while, the use of 
His-Trap™ column did not give such results and required further purification steps. A 
possible reason for this is the use of the metal ion in the binding resin. The TALON® 
Superflow™ Affinity Resin used Co2+ ions which can bind with more specificity and 
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strength to the 6X His-tag than the Ni2+ ion present in the resin of the His-Trap™ 
column. Another possible reason attributed to the difference in the purification 
process was the volume of the sample being purified. Although, we obtained 
recombinant MsrB3A protein with high degree of purity on bench scale, the amount 
purified protein was not sufficient for structural studies and functional assays. 
Hence, increasing the sample volume also increases the concentration of other 
unwanted histidine containing proteins which were the contaminants and were 
subsequently removed by further chromatographic purification processes. 
 
3.3.2 Structural studies of recombinant MsrB3A 
The CD spectroscopic and NMR spectroscopic structural studies conducted on 
recombinant MsrB3A protein did confirm that the protein was folded, but whether it 
was correctly folded to be functional was not known. The functional studies made, 
as discussed in the chapter 4 and 5 proved that our recombinant protein was 
functional, hence, establishing that the recombinant MsrB3A was folded in its 
correct conformation. Though CD spectroscopy and NMR spectroscopy could shed 
some light on the structure of MsrB3A and change in the conformation when MsrB3A 
was reduced by TCEP, further experiments must be made to understand and solve 
the structure of MsrB3A protein. 
Though some hits were achieved for screening of crystallisation conditions, 
but on analysis they either turned to be salt crystals or ceased at the phase 
separation stage. Therefore, the crystal trials were not successful. Further 
experiments using new crystallisation parameters must be made to obtain better 
crystals.   
 
3.4 Future work 
From the results obtained in this chapter, much work requires to be done to 
determine the structure of MsrB3A protein. For example, for CD and NMR 
spectroscopy, further experiments involving thermal stability of MsrB3A protein, 
analysis of structural conformations of MsrB3A mutant proteins and their subsequent 
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comparison with the results obtained for the wild-type MsrB3A protein are some of 
the experiments which could be made.  
From the results obtained in the subsequent chapters about the functionality 
of MsrB3A protein demonstrates that the MsrB3A protein is functional, thereby, 
proving that the conformation achieved for the recombinant MsrB3A protein is 
correct. Hence, we could then design an experiment to study the changes in the 
conformation of MsrB3A when it reduces the methionine sulfoxide to methionine in 
presence of a reducing environment using cryo-NMR spectroscopy. This experiment 
would also provide us an actual glimpse into the mode of function of MsrB3A protein. 
Though the NMR spectroscopy could provide us with valuable insight into the 
structure of MsrB3A protein and helps us to collect information from different types 
of experiments easily, the resolving power of NMR spectroscopy is lower than x-ray 
crystallography as the information obtained is highly complex and requires more 
sophisticated equipment to handle the data-sets obtained. On the other hand, we 
can obtain the entire 3D structure at atomic scale by systematic analysis of data 
obtained by x-ray crystallography. As we know from our results obtained earlier in 
this chapter, we were not successful in obtaining protein crystals that are suitable 
for X-ray crystallographic studies. A possible reason for this could be the 
interference caused by the presence of the 6X His-tag. Hence, to remove the His-tag 
from the recombinant MsrB3A protein we need to treat the recombinant MsrB3A with 
TEV protease in presence of a suitable cleavage buffer which would cleave the His-
tag from the recombinant protein allowing it to be separated easily by HPLC, while 
the His-tag remains attached to the column resin. The His-tag could then be washed 
using the suitable elution buffer. This way we might be able to get the tag free 
MsrB3A protein which we could analyse for its structure and function, as well as, it 
could be helpful to get protein crystals that might be suitable for structural studies.  
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Chapter 4: Creation of C126A MsrB3A mutant by 
site-directed Mutagenesis. 
4.1 Introduction 
 
In the previous chapter, we discussed the need to study MsrB3A protein, how 
it was cloned, expressed and purified from recombinant E. coli cells, followed by 
structural studies using CD spectroscopy, NMR spectroscopy and protein crystal 
trials. From the experiments conducted by CD spectroscopy and NMR spectroscopy, 
it is observed that the MsrB3A protein has a folded structure, but whether it is in its 
correct conformation, can only be proved if the protein is functional. As discussed in 
the later chapters, MsrB3A is a functional protein signifying that the structural 
conformations obtained by CD and NMR spectroscopy are correct. But to validate 
and understand about the arrangement of amino acids involved in the functioning of 
the protein, mutant proteins having altered sequences by substitution, insertion or 
deletion of amino acid residues based on conserved regions obtained by sequence 
alignment (Fig. 3.1), are created to study the effects of mutation and understand 
their role in the proper functioning of the protein. Alteration of the amino acid 
sequences can be brought about by the help of site directed mutagenesis in the 
respective gene sequence encoding for the mature protein.   
From literature, it is known that, mammalian MsrB (SelR) consists of a seleno-
cysteine residue towards the C-terminal of the protein chain, which is said to be 
responsible for the catalytic activity of the protein. Hence, it can be used as a good 
indicator of a catalytic residue which is vital for the redox reactions when compared 
for finding the catalytic residue in various MsrB sequences (Stadtman, 1996, Hatfield 
and Gladyshev, 2002). From multiple sequence alignment (Fig. 3.1), we observe that 
a single cysteine residue near the C-terminal is conserved in the various MsrB 
sequence and shows conservation with the seleno-cysteine residue of the human and 
mouse MsrB1 (SelR) sequences. In case of the MsrB3A sequence, the 126th position 
cysteine corresponds as the conserved cysteine residue, which is also in alignment 
with the seleno-cysteine residue. 
Based on the multiple sequence alignment and literature stated in the last 
paragraph, we hypothesise that the 126th position cysteine is the catalytic residue 
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which is responsible for the redox process in MsrB3A protein and is present in the 
active site of MsrB3A protein. Hence, we mutated the MsrB3A protein by substituting 
the 126th position cysteine for alanine to produce a non-functional protein using site-
directed mutagenesis.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Page | 66  
 
 
4.2 Results 
 
4.2.1 Site directed mutagenesis 
 
As discussed earlier in section 2.4.1, synthetic DNA primers incorporating the 
cysteine to alanine mutation (TGC→GCC) at the 126th position of the amino acid 
sequence of MsrB3A, were amplified using nested PCR on the parental DNA strand 
(mature DNA sequence for the recombinant MsrB3A protein) and subsequently 
transformed into recombinant E. coli XL1 Blue super-competent cells. The 
transformed cells were then grown over-night in selective LB agar media containing 
0.1 mg/ml ampicillin at 37°C, following which the plasmid DNA was isolated using 
alkaline lysis method. The resulting plasmid DNA was sequenced by GATC Biotech. 
Potential DNA sequences predicted to contain the mutation were aligned 
together with the mature DNA sequence of the recombinant MsrB3A gene lacking the 
signal peptide (Fig. 4.1). As we can clearly observe from the multiple sequence 
alignment (Fig. 4.1), the C126A MsrB3A mutant DNA sequences 1, 2, 3, 7 and 9 had 
the mutation, i.e., TGC→GCC, which could encode alanine in place of cysteine at 
the 126th position of the amino acid sequence during translation (Fig. 4.2). But only 
the DNA sequence of the mutated gene sequence 9, could encode the entire gene 
sequence of the MsrB3A protein, as seen in Fig. 4.2. Although, the mutated gene 
sequence for the C126A MsrB3A mutant sequence 1 had a better DNA purity profile 
(Fig. 4.3) than the DNA sequence of C126A MsrB3A mutant sequence 9, since, it just 
lacked the DNA sequence to encode the last six amino acids at the C-terminal (as 
seen in Fig. 4.2), it could not be used further to produce the mutant C126A MsrB3A 
protein. 
Thus, the plasmid DNA containing the C126A MsrB3A mutant DNA sequence 9 
was used to transform the recombinant E. coli BL21 (DE3) Star pLysS cells to express 
the recombinant C126A MsrB3A mutant protein. The expression of the mutant 
protein, extraction and purification are discussed in detail in the next section.     
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Figure 4.1:  Multiple sequence alignment of 
the mature wild-type MsrB3A DNA 
sequence with the DNA sequence of C126A 
MsrB3A mutants containing the mutation 
TGC→GCC to substitute Cys to Ala.  
C126A MsrB3A mutant DNA sequences 5, 6, 
and 12 are incomplete sequences and do 
possess the mutation codon. Sequences 1, 2, 
3, 7 and 9 contain the mutated region coding 
for Ala residue (highlighted and magnified to 
show mutation), but only sequence 9 
encodes the entire protein and is in full 
alignment with the wild-type MsrB3A DNA 
sequence. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Page | 68  
 
Figure 4.2:  Multiple sequence alignment of the mature wild-type MsrB3A amino acid sequence with 
the translated amino acid sequence of C126A MsrB3A mutants showing the mutation (substitution) 
Cys→ Ala.  
The highlighted region shows the substituted mutation of Cys to Ala. The mutant sequences 1, 2, 3, 7 and 
9 all contain the mutation region, but only sequence 9 shows full alignment with the wild-type amino acid 
sequence for MsrB3A protein. 
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4.2.2 Protein expression, extraction and purification 
 
To express the recombinant C126A MsrB3A mutant protein, the transformed E. 
coli cells were first grown in selective LB broth media and then induced for protein 
expression using IPTG. The expression was then analysed on 15% SDS-PAGE gel 
(result not shown). No expression was observed in LB broth media. Similar results 
were also obtained when the recombinant E. coli cells containing the C126A MsrB3A 
mutant gene was expressed in TB media (Fig. 4.4 Panel A). There was no increase in 
the protein expression when induced by IPTG. Although, a leaky expression for the 
C126A mutant protein was observed in TB broth media.  Hence, depending on the 
leaky expression obtained for the C126A MsrB3A protein we proceeded to extract the 
recombinant protein using French Press. Fig. 4.4 Panel B demonstrates the 
extraction samples when analysed on SDS-PAGE gel. As we can clearly observe, only 
a small quantity of the C126A MsrB3A mutant protein is obtained in the supernatant 
(Sn) or clarified solution. The clarified solution was then filtered as discussed in 
section 2.2.1, before being purified by IMAC chromatography using the AKTA FPLC 
system. 
 
Fig. 4.5 represents the purification of the C126A MsrB3A mutant protein by 
IMAC chromatography. As we can clearly observe in lanes 3 to 13 of panel B, there 
are still some higher molecular weight contaminants present after IMAC 
chromatography purification. In panel A, we observe that two different peaks are 
present which may denote the presence of different forms of the mutant C126A 
MsrB3A protein, which gets eluted at different time interval. The IMAC purified 
samples are further purified by gel filtration chromatography (Fig. 4.6). In panel A 
we notice the presence of multiple peaks, which might suggest that the purified 
C126A MsrB3A mutant protein has multiple structural forms in which it gets eluted or 
the protein might be cleaved by the E. coli proteases resulting in multiple peptides. 
However, we only use the samples from the lanes 8 to 9 for further study, as the 
other samples contain a lot of contaminant proteins and less quantity of our target 
mutant protein. The gel filtration chromatography eluted C126A MsrB3A mutant 
protein samples were then collected, concentrated and quantified according to the 
procedure stated in section 2.2.2. Though, the quantity of C126A MsrB3A mutant 
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protein obtained was small but was sufficient to perform functional studies related 
to MsrB3A protein.  Another noticeable feature in the extraction and purification 
steps of C126A MsrB3A mutant protein was the absence of the bands between the 32 
to 46 KDa marker in the selected purified samples of gel filtration chromatography, 
unlike the observations made in the extraction and purification steps of wild-type 
MsrB3A protein.  
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Figure 4.4:  Protein expression and extraction of C126A MsrB3A mutant. 
Lane M represents the Blue Pre-Stained Protein Standard in both panels.  
Panel A represents the SDS-PAGE gel analysis for protein expression of C126A MsrB3A mutant in TB broth 
media. Lane 1 contains the sample from cell culture before IPTG induction, while lane 2 represents the 
sample from cell culture after IPTG induction. 
Panel B represents the SDS-PAGE gel analysis for protein extraction of C126A MsrB3A mutant using French 
Press. Lane E represents extraction sample after cell lysis using French Press. Lanes P and Sn represent the 
pellet and supernatant respectively. 
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Figure 4.5:  Immobilised metal affinity chromatography (IMAC) purification of C126A MsrB3A mutant 
protein. 
A.  Graph representing a typical FPLC chromatogram obtained using a 5 ml HisTrap™ HP affinity column 
for purifying the 6X His-tagged C126A MsrB3A mutant protein. The bound protein was eluted by using a 
500 mM Imidazole concentration gradient represented by the orange curve. 
 
B. SDS-PAGE gel analysis of the samples of the purified fractions collected from the peaks obtained as 
shown in graph. Lane 1 in illustration B represents the sample from the flow through elution peak, 
while lanes 3 to 13 represent the samples from the fractions collected from the MsrB3A elution peak in 
successive order and is represented in graph A by the double headed arrow. 
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Figure 4.6: Gel filtration chromatography purification of C126A MsrB3A mutant protein.  
A. Graph representing a typical FPLC chromatogram obtained using a Superdex 200 10/300 GL gel 
filtration chromatography column for purifying the C126A MsrB3A mutant protein based on the 
principle of molecular size exclusion. 
 
B. SDS-PAGE gel analysis of the samples of the purified fractions collected from the peaks obtained as 
shown in graph. Lane M represents the Blue Protein Standard used as reference. Lanes 8 to 10 
represent the samples from the fractions collected from the elution peak in successive order and is 
represented in graph A by the double headed arrow.  
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4.2.3 Discussions 
From the results obtained above, we could mutate the mature MsrB3A DNA 
sequence to encode for alanine residue in place of conserved cysteine residue at the 
126th position of the MsrB3A protein sequence, as seen in Fig.5, using site directed 
mutagenesis. The C126A MsrB3A mutant protein was further used to verify the 
function of MsrB3A protein as discussed in the next two chapters. 
A striking feature which we notice from Fig. 25 is the presence of multiple 
elution peaks in panel A. In panel B, the elution samples from these peaks show the 
presence of the mutant MsrB3A protein but in mixture with other contaminant 
proteins. This suggests that the C126A MsrB3A protein is not only unstable, but it 
may also signify that the cysteine residue which was substituted might also be 
responsible for maintaining the structural conformation of the protein. Although, we 
could get some insight about the structural integrity of MsrB3A, more mutagenesis 
studies are required to have a better understanding. Besides the creation of more 
MsrB3A mutants, the use of different MsrB3A mutants for structural studies is 
another field which could provide more detailed insight about the structural 
conformation and integrity of MsrB3A. 
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Chapter 5: MsrB3A functional assay I – Gel shift 
assay 
5.1 Introduction 
In the previous chapters, we discussed the expression of human MsrB3A 
protein in recombinant E. coli cells, followed by its extraction, purification and 
structural studies. We also created the C126A mutant MsrB3A (substituting alanine in 
place of cysteine at 126th position of the amino acid chain) for functional analysis of 
MsrB3A. 
From the literature, we know that different assays have been developed over 
time to study the functions of methionine sulfoxide reductases. The first such 
functional assay for methionine sulfoxide reduction was developed by (Brot et al., 
1982). The method utilised [3H]-labelled N-acetyl methionine sulfoxide as the 
substrate and used ethyl acetate extraction to assay the radioactive N-acetyl 
methionine obtained after reduction by methionine sulfoxide reductases. Some 
major drawbacks of this technique included the use of radioactive isotopes, 
incomplete extraction of the reaction product and contamination of the substrate. 
Another method commonly utilised for determination of Msr function is an enzyme-
coupled method that depends on the change in absorption of light by NADPH at 340 
nm as described by (Moskovitz et al., 1996). In the method, the Msrs are reduced by 
thioredoxin which in turn is reduced by the NADPH-dependent thioredoxin 
reductase, thereby, utilising the change in the absorption of light by NADPH at 340 
nm for determining Msr function. Although, the detection by this method is slightly 
less than the HPLC assay which utilises dabsylated methionine sulfoxide as substrate 
for Msrs, it allows to experiment with different substrates.  
The HPLC assay is another method which is commonly utilised for 
determination of Msrs functions. As stated earlier it uses the reduction of dabsylated 
methionine sulfoxide to dabsylated methionine by Msrs, and is highly accurate and 
sensitive. We shall be discussing this technique further in chapter 6. The only 
drawback of the technique is that it utilises a HPLC system for separating the 
dabsylated methionine sulfoxide from dabsylated methionine, hence, requiring the 
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use of skilled labour for operating the system, as well as, for preparation of the 
substrate. Yet with recent developments in the HPLC systems it is becoming much 
easier to use this method to assay methionine sulfoxide reductases. 
Recently, a more simple, easy and cost-effective method has been developed 
by (Le et al., 2008), which utilises the mobility shift of methionine-rich proteins 
between their oxidised and reduced states when analysed on SDS-PAGE gels for 
determining the function of different methionine sulfoxide reductases. In this 
method, it was noted that the oxidised forms of the methionine-rich proteins 
exhibited decreased mobility than their reduced forms.  An improved version of the 
method was devised by (Gennaris et al., 2015), in which methionine-rich proteins 
such as, SurA, Pal, calmodulin etc., found in the bacterial cell envelope of 
important human pathogens, was utilised widely to determine the function of the 
novel MsrPQ reduction enzymes. Hence, we used SurA as our model substrate using 
this technique to determine the function of MsrB3A as discussed later in the chapter.       
SurA is a chaperone protein that occurs mostly in the periplasm of gram 
negative bacteria. It aids in the folding and transport of outer membrane proteins in 
the periplasmic space of the bacteria (Vertommen et al., 2009). SurA has 14 
methionine residues present in it, which makes it highly susceptible to attack by 
reactive oxygen species (ROS) (Gennaris et al., 2015, Riley et al., 2006). Since, SurA 
serves as one of the vital proteins responsible for biogenesis of the cell membrane in 
gram negative bacteria (Volokhina et al., 2011), hence, it can be used as an 
excellent biological substrate to determine the functionality of human MsrB3A.  
Hence, SurA was over-expressed as described in section 2.5.1. It was then 
extracted and purified using the same methods described in section 2.2.1, except 
the desalting and ion exchange chromatography steps which were not required in 
this case. 
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5.2 Results 
 
5.2.1 Protein expression, extraction and purification- 
 
Fig. 5.1 represents the SDS-PAGE gels for the SurA protein expression (panel 
A) and extraction (panel B) respectively. Panel A represents the expression of SurA 
before (lane1) and after (lane 2) being induced by IPTG respectively. As we observe 
in panel A, over-expression of SurA occurs when induced by IPTG, resulting in high 
quantities of the protein as shown by the thick band in lane 2. This also suggests 
that the product obtained is also stable and does not degrade rapidly. 
 
 In Panel B (Fig. 5.1), the SDS-PAGE gel represents the extraction of SurA using 
a French Press. Presence of a thick and distinct band in lane Sn suggests that the 
protein is soluble and is present in the supernatant, but presence of a distinct band 
in lane P tells us that a small fraction is still present in the pellet. This could be due 
to the inefficiency of the cell lysis step caused by low pressure applied by the piston 
leading to generation of lower shear stress and insufficient cycles in the French 
Press, for which a fraction of cells remained intact. 
 
 Fig. 5.2 represents the purification of SurA by immobilised metal affinity 
(IMAC) chromatography.  As we can observe in lanes 2-4 of panel B, there are a few 
higher molecular weight contaminants still present after purification by IMAC 
chromatography. Hence, the IMAC purified samples were further purified by gel 
filtration chromatography as shown by Fig. 5.2. After purification, the samples 
collected were concentrated down, quantified and aliquoted as described in section 
2.2.2.  
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Figure 5.1:  Protein expression and extraction. 
Lane M represents the Blue Pre-Stained Protein Standard in both panels.  
Panel A represents the SDS-PAGE gel analysis for protein expression of SurA. Lane 1 contains the sample 
from cell culture before IPTG induction, while lane 2 represents the sample from cell culture after IPTG 
induction. 
Panel B represents the SDS-PAGE gel analysis for protein extraction of SurA. Lane E represents extraction 
after cell lysis using French Press. Lanes P and Sn represents the pellet and supernatant respectively. 
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Figure 5.2:  Immobilised metal affinity chromatography (IMAC) purification of SurA protein. 
A.  Graph representing a typical FPLC chromatogram obtained using a 5 ml HisTrap™ HP affinity column 
for purifying the 6X His-tagged SurA protein. The bound protein was eluted by using a 500 mM 
Imidazole concentration gradient represented by the orange curve. 
 
B. SDS-PAGE gel analysis of the samples of the purified fractions collected from the peaks obtained as 
shown in graph. Lane F.T. in illustration B represents the sample from the flow through elution peak, 
while lanes 2 to 6 represent the samples from the fractions collected from the MsrB3A elution peak in 
successive order and is represented in graph A by the double headed arrow. 
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Figure 5.3: Gel filtration chromatography purification of SurA protein.  
A. Graph representing a typical FPLC chromatogram obtained using a Superdex 200 10/300 GL gel 
filtration chromatography column for purifying the SurA protein based on the principle of molecular 
size exclusion. 
 
B. SDS-PAGE gel analysis of the samples of the purified fractions collected from the peaks obtained as 
shown in graph. Lane M represents the Blue Protein Standard used as reference. Lanes 1 to 4 
represents the samples from the fractions collected from the SurA elution peak in successive order 
and is represented in graph A by the double headed arrow.  
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5.2.2 Gel shift assay 
 
As discussed earlier in the chapter 5 introduction, the gel shift assay is 
employs the shift or change in the mobility of methionine-rich proteins between 
their oxidised and reduced states when analysed on SDS-PAGE gel to determine the 
function of Msrs (Le et al., 2008). Since, SurA contains 14 methionine residues on its 
surface, hence, it can get rapidly oxidised by oxidising agents (in this case by 
incubating SurA with 100 mM H2O2 at 30°C for 3 hours in 20 mM HEPES and 150 mM 
NaCl, pH 7.5 buffer) to form methionine sulfoxide which in turn increases the 
molecular mass of the protein. Therefore, when analysed on SDS-PAGE gel the 
oxidised SurA moves slower than its reduced or untreated state, resulting in a 
mobility shift as illustrated by Fig. 5.4 panel A. The band of the oxidised SurA (lane 
2) is higher than the band of the untreated or reduced SurA sample indicating that 
oxidised SurA travels slower than the untreated or reduced sample. Similar results 
were also found by (Gennaris et al., 2015), when SurA was oxidised using H2O2. 
Another notable feature was that when the SurA samples were treated with DTT, 
but there was no effect on the mobility, indicating that DTT has no effect on the 
mobility of SurA. Similar situations were also observed by (Le et al., 2008), when 
other methionine rich proteins were oxidised and treated with DTT, thereby, 
indicating that DTT cannot reduce methionine sulfoxide on its own and requires a 
reagent with higher reducing power. Hence, based on the principle of mobility shift 
of the methionine-rich proteins, different experiments were devised varying in 
parameters in which the oxidised SurA was treated with MsrB3A to reduce it in the 
presence and absence of DTT, as shown in Fig. 5.5.  
 
In Fig. 5.5, we can observe a small shift in the mobility of oxidised SurA 
towards the mobility of its reduced state, but not entirely when it is treated with 
MsrB3A in presence of DTT (lane 4), suggests that MsrB3A in presence of DTT alone 
cannot return SurA back to its original mobility. This might indicate that MsrB3A is 
stereo-specific to some extent. A slight shift is also observed in lane 5 when oxidised 
SurA is treated with MsrB3A in the absence of DTT, but is less evident in contrast to 
the mobility of the oxidised SurA when treated with MsrB3A in the presence of DTT. 
Although, there are slight shifts in the mobility of SurA when treatedby MsrB3A in 
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presence (lane 4) and absence (lane 5) of DTT, but are not as significant as the Sur A 
mobility shift assays obtained by (Gennaris et al., 2015). 
 
In Fig. 5.6, panels A and B represent the gel shift assay when oxidised SurA is 
treated with MsrB3A at different concentration ratio (MsrB3A: SurA) of 1:1, 1:2, 1:5, 
1:10, 1:100 and 1:1000, in the presence and in the absence of DTT respectively 
(lanes 3-8).  Although slight shifts are detected, they are not too clear to draw 
definite conclusions. Panel C represents the gel shift assay in which oxidised SurA is 
treated with equal quantity of MsrB3A in presence and absence of DTT (lanes 3 and 4 
respectively), as well as, when it was treated with equal amount of MsrB3A C126A 
mutant again in presence and absence of DTT (lanes 5 and 6 respectively). Similarly, 
to panels A and B, slight shifts can be seen but are very hard to distinguish and draw 
clear conclusions. It should also be noted that the shifts observed in lanes 3 to 6 are 
similar.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Page | 84  
 
Figure 5.4:  Gel shift assay (mobility of SurA)   
Panel A represents the SDS PAGE gel showing change in the mobility of SurA when it is oxidised. Lane 1 represents the 
untreated SurA and lane 2 represents oxidised SurA. Lane 2 is higher than lane 1 indicating shift in mobility of the 
protein. 
Panel B depicts the typical chromatogram of separating the oxidised SurA after treatment with H2O2.     
Figure 5.5:  Gel shift assay (functional assay of MsrB3A)-I. SDS-PAGE gel depicting the different conditions of 
oxidised SurA when treated with MsrB3A and DTT.  
Lane 1 represents SurA in its native state, lane 2 contains the SurA sample when treated with DTT, lane 3 contains the 
oxidised SurA sample, while lanes 4 and 5 represent the oxidised SurA sample after it was treated with equal molar 
concentrations of wild-type MsrB3A under reducing and non-reducing conditions in presence and absence of DTT, 
respectively. 
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Figure 5.6:  Gel shift assay (functional assay of MsrB3A)-II 
A. SDS-PAGE gel representing the shift in the mobility of oxidised SurA samples when treated with different 
concentrations (1X, 2X, 5X, 10X, 100X and 1000X dilution) of MsrB3A represented by lanes 3 to 8 under reducing 
conditions, in the presence of DTT. Lanes 1 and 2 contains untreated or native SurA sample and oxidised SurA 
samples, respectively. 
B. SDS-PAGE gel representing the shift in the mobility of oxidised SurA when treated with different concentrations 
(1X, 2X, 5X, 10X, 100X and 1000X dilution) of MsrB3A represented by lanes 3 to 8 under non-reducing conditions, 
in the in absence of DTT. 
C. SDS-PAGE gel representing shift in SurA mobility when treated with equal concentrations of MsrB3A or MsrB3A 
C126A mutant in presence and absence of DTT, alternatively and are represented by the lanes 3 to 6. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Page | 86  
 
5.3 Discussions 
From the results obtained above, we could predict the following conclusions 
from the gel shift assay, though the results obtained do not hold much significance 
and are mostly not clear to draw definite conclusions. First, the MsrB3A protein 
might be stereo-specific in nature, as all the figures indicate a slight shift in the 
mobility of the oxidised SurA when it is treated with MsrB3A enzyme, but the shift 
does not occur all the way to the original mobility indicating that SurA is partially 
repaired and a fraction of methionine residues might still be oxidised. Similar 
situation was also observed by Gennaris et al., 2015, when they had treated the 
oxidised SurA with MsrP enzyme only in contrast to the treatment of the oxidised 
SurA by MsrPQ reduction system, which could successfully reduce the oxidised SurA 
back to its native form. But the stereoisomer that is reduced by MsrB3A is still not 
confirmed, though from literature it is said to be R-isoform of methionine sulfoxide 
(Kim and Gladyshev, 2004b). Hence, we need to have further experiments to prove 
that R-form of methionine sulfoxide is reduced by MsrB3A.  
From the literature, it is known that DTT cannot reduce oxidised methionine 
residues in SurA and requires a reagent with higher reducing strength (Gennaris et 
al., 2015). The same was also observed in Fig. 5.6 panel A. The oxidised SurA had no 
effect in the reducing environment caused by the presence of DTT, hence, the 
mobility shift of oxidised SurA was observed, indicating SurA is independent of 
reduction by DTT and requires Msrs to be reduced back to its native state.  
In Fig. 5.6 panel C, we can observe that there is no difference in the mobility 
shifts when oxidised SurA was treated with wild-type MsrB3A and C126A MsrB3A 
mutant. This indicates that either the C126A MsrB3A mutant was functional and the 
mutation of cysteine does not affect the protein activity of MsrB3A or there is no 
separation at all. This is mainly attributed for the low resolution of the gel, which 
could be responsible for the negligible to no separation observation. 
Although, the gel shift assay is a cheap and easy way to determine the protein 
function of Msrs, the lack of clear and definitive separation of the oxidised and 
repaired forms in our experiments clearly indicates the drawbacks of this method. 
To obtain clear and distinct bands with good separation, the gel shift assay requires 
a lot of manipulation and optimisation of different factors involved with SDS-PAGE 
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electrophoresis. For example, the sample concentration added to the SDS-PAGE gels 
requires a lot of trial and error to obtain distinct and sharp bands, which could help 
distinguish and analyse protein function. Percentage composition of the SDS-PAGE 
gels and the voltage applied across the gel are some other factors which govern the 
success of this technique. Another major drawback of the technique is that it cannot 
identify the stereo-specificity of the Msr enzyme, unless a pure Msr enzyme of 
known origin and function with high degree of purity is used in conjugation with our 
target Msr. Hence, the overall conclusion which could be made is that the results 
obtained by gel shift assay is not credible enough to draw adequate conclusions and 
requires further experimentation to get better results. 
Yet, with further experimentation and better understanding of the different 
methionine-rich proteins, the gel shift assay could be effectively used in future for 
establishing the function of different Msrs.  
5.4 Future work 
To improve the results obtained by gel shift assay, we can experiment further 
with different percentage gels, preferably on 7.5% and 12.5% SDS-PAGE gels to 
determine which offers better separation. Optimisation of the voltage applied across 
the gel or current flowing through the gel would help further benefit the get better 
resolution.  
Other future experiments which could be done include the use of MsrA-
MsrB3A conjugate system in presence of DTT, which might help us to determine the 
true stereo-specificity of MsrB3A, provided the MsrA enzyme used is from a known 
origin and of high purity. Use of other methionine-rich proteins which has a better 
separation between their oxidised and reduced states.  
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Chapter 6: MsrB3A functional assay II- 
HPLC assay  
 
6.1 Introduction 
In the previous chapter, we discussed the different types of assays used for 
determining the function of different Msrs throughout literature. A recent technique 
which has emerged to determine the functions of Msrs is the gel shift assay which we 
described in detail in the last chapter. Although the gel shift assay is a cheap and 
easy technique to perform, it has several drawbacks. First it could not provide a 
clear overview of the MsrB3A function, due to the lack of definitive separation 
between the oxidised and repaired states of the methionine-rich proteins (in this 
case SurA). Secondly, it lacks the ability to identify the stereo-specificity of the Msr 
enzyme unless conjugated with an Msr of known function and origin. Therefore, the 
HPLC assay is another method which is widely used to have a better understanding 
of the MsrB3A function and help to evaluate the results obtained from gel shift 
assay. 
The method utilises the dabsylated derivatives of methionine sulfoxide and 
methionine (Minetti et al., 1994), thus making it easier to observe the reduction of 
methionine sulfoxide to methionine by monitoring the absorption of light at 436 nm 
(Kryukov et al., 2002). Also, both dabsylated methionine sulfoxide and dabsylated 
methionine have different retention time within the reverse phase HPLC column. 
Hence, they could be separated easily from each other. The major advantage of this 
technique is its high accuracy and sensitivity, with minimum requirement of reaction 
substrates. Another advantage of this method is that, individual dabsylated 
isoforms, i.e., either the methionine-R-sulfoxide or methionine-S-sulfoxide or a 
racemic mixture of methionine-RS-sulfoxide could be synthesised for study of the 
Msr function. The drawback of the technique includes the utilisation of the HPLC 
system which requires skilled labour for handling and the substrate preparation 
which is difficult and time consuming. Although, recent developments in the HPLC 
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system has made the use of such systems more user-friendly, hence, allowing 
greater possibility of the use of this technique. 
From sequence alignment (Fig. 3.1), we notice that the MsrB sequences have 
5 sets of conserved cysteine residues. From the literature, we know that four of the 
cysteine residues organised in form of -CXXC- motifs are responsible for Zn2+ binding 
(Kumar et al., 2002) and the conserved cysteine residue present towards the C-
terminal region of the MsrB sequence might be responsible for enzyme catalysis due 
to the presence of seleno-cysteine (represented as U in the amino acid sequence) 
residue in mammalian MsrB1 protein which is an indication of the catalytic residue 
involved in the redox processes (Kim and Gladyshev, 2007, Kim and Gladyshev, 
2004b). Hence, we use an improved version of the HPLC assay as described by 
(Kumar et al., 2002), for determining the protein function of human MsrB3A protein 
and the results so obtained from the technique are described below in detail.  
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6.2   Results 
As stated earlier, the dabsyl group has maximum absorbance of light at 436 nm. 
Hence, the dabsylated methionine and dabsylated methionine sulfoxide were first 
eluted using the C-18 reverse phase column to determine their retention time in the 
column, to be used as reference for further experiments. Fig. 6.1 illustrates the 
typical HPLC elution profile of dabsylated methionine sulfoxide (panel A) and 
dabsylated methionine (panel B) respectively. As we can see from Fig. 6.1 panel A, 
dabsylated methionine sulfoxide elutes from the column after 20 minutes, while in 
panel B dabsylated methionine has a retention time of nearly 25 minutes.  
As explained earlier in section 2.5.2, the dabsylated methionine sulfoxide was 
treated with MsrB3A in presence of DTT at different times- 5, 10, 20 and 30 minutes. 
The reaction was then stopped using 0.5% SDS and the reaction products were 
separated using the C-18 reverse phase chromatography column. Fig. 6.2 illustrates 
the elution profile of dabsylated methionine and methionine sulfoxide obtained after 
treatment with MsrB3A at different time intervals. As we can clearly observe in Fig. 
6.2, only a part of the dabsylated methionine sulfoxide is reduced back to methionine 
(approximately half the peak size obtained for dabsylated methionine sulfoxide), as a 
racemic mixture of dabsylated methionine-RS-sulfoxide was used as substrate. This 
could be due to the other isoform of methionine sulfoxide which is not a substrate for 
MsrB3A, also verifying that the enzyme is stereo-specific in nature, as stated by 
(Kryukov et al., 2002) as well. Although, only half the fraction of the dabsylated 
methionine sulfoxide gets reduced, whether it is the R- or S- isoform of methionine 
sulfoxide being reduced, is still required to be proved by further experimentation.  
It can also be observed that the elution peak of dabsylated methionine becomes 
constant after 10 minutes and no net changes are observed in the peaks, indicating 
that the reaction takes only about 10 minutes to complete in presence of a recycling 
environment (in this case provided by DTT).  
Another observation is that the peak for dabsylated methionine occurs at 25 
minutes rather than after it, as shown in Fig. 6.1 panel B. This is due to difference in 
the flow rates. The flow rate of the reference dabsylated methionine was 0.45 
ml/min, while flow rate used in the functional assay was 0.5 ml/min, resulting in the 
difference in the retention time.  
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Fig. 6.3 represents the elution profile of dabsylated methionine sulfoxide when 
it was treated with MsrB3A C126A mutant in presence of DTT. As we can observe, 
there is no difference in the elution profile between elution profile for dabsylated 
methionine sulfoxide and the elution profile obtained when dabsylated methionine 
sulfoxide was treated with the C126A MsrB3A mutant protein. This indicates 2 major 
aspects. First, the mutant is non-functional and is unable to reduce the dabsylated 
methionine sulfoxide. Secondly, the 126th position cysteine that was mutated 
(substituted with alanine) is required for the proper functioning of the protein, and 
might be present in the active site of the protein. Similar results were also obtained 
by (Kumar et al., 2002), indicating that the 126th position cysteine is the catalytic 
cysteine responsible for reducing the methionine sulfoxide to methionine. 
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Figure 6.1: HPLC assay  
A. Graph representing a typical elution profile of dabsylated methionine sulfoxide 
represented by the blue curve, while the gradient of the elution buffer is expressed by 
the orange curve.  
B. Graph representing a typical elution profile of dabsylated methionine represented by 
the blue curve, while the gradient of the elution buffer is represented by the orange 
curve. 
A. 
B. 
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Figure 6.2: HPLC assay:  Graphs representing the typical elution profile of dabsylated 
methionine sulfoxide and methionine after treatment of dabsylated methionine sulfoxide for 5, 
10, 20 and 30 minutes with MsrB3A in presence of DTT, shown by the curve in blue. The orange 
curve shows the gradient profile for the elution buffer. 
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Figure 6.3: HPLC assay:  Graph representing the typical elution profile of dabsylated 
methionine sulfoxide after treatment with MsrB3A C126A mutant for 30 minutes in presence of 
DTT, shown by the blue curve. The orange curve represents the gradient profile for the elution 
buffer. 
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6.3 Discussions 
From the results obtained by HPLC assay, we can conclude that the MsrB3A 
protein is stereo-specific in nature as we can clearly observe in Fig. 6.2. Since, only 
a part of the dabsylated methionine sulfoxide is reduced back to methionine by 
treatment of dabsylated methionine sulfoxide with MsrB3A in presence of DTT, along 
with the appearance of dabsylated methionine curve clearly indicates that MsrB3A is 
stereospecific in nature. But the stereospecificity type of MsrB3A could not be 
answered in the experiment as dabsylated methionine-RS-sulfoxide was used as 
substrate for the experiment. Though from literature, we know that MsrB3A is 
specific for the R-form of methionine sulfoxide (Kim and Gladyshev, 2004b), but 
further experiments involving only dabsylated methionine-R-sulfoxide should be used 
as substrate for reduction (as stated by (Kumar et al., 2002)) or a MsrA protein of 
known function, origin and high purity should be used in conjugation with MsrB3A 
protein for future experiments to identify the stereo-specificity of MsrB3A protein. 
Another noticeable feature is that, the reduction of dabsylated methionine 
sulfoxide only takes 10 minutes to complete, as observed in Fig. 6.2 panels A to D. 
We observe no change in the elution peak of the dabsylated methionine obtained 
after 10 minutes in the further experiments. This could help us determine the 
specific reactivity of MsrB3A protein on further experimentation by plotting the 
substrate consumption against the time spent for reduction at 1 minute intervals.  
Fig. 6.3 illustrates the HPLC assay of dabsylated methionine sulfoxide when 
treated with C126A MsrB3A mutant. As we can clearly observe that there is no 
reduction which takes place signifying that the mutant is non-functional. Contrary to 
the results obtained by gel shift assay, the HPLC assay clearly suggests that the 
C126A MsrB3A mutant protein was non-functional and that the 126th position 
cysteine could be a catalytic cysteine which is present at the active site of the 
protein as stated by (Kumar et al., 2002) and shown as a conserved residue in 
multiple sequence alignment (Fig. 3.1). 
Although, the HPLC assay has provided us with valuable insight in to the 
function of MsrB3A to understand the functional mechanism of MsrB3A enzyme, 
further experiments are required which are discussed in detail the next section. 
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6.4 Future work 
First step is to identify the stereo-specificity of MsrB3A protein by either 
analysing the reduction of dabsylated methionine-R-sulfoxide as stated by (Kumar et 
al., 2002) or by using MsrA enzyme of known function, origin and high purity in 
conjugation with MsrB3A protein to reduce the dabsylated methionine-RS-sulfoxide 
utilising the same procedure used initially for determination of MsrB3A function. 
Following determination of MsrB3A stereo-specificity, kinetic studies to 
determine the specific reactivity of MsrB3A experimentally should be done by 
plotting the amount of substrate consumption with respect to time at 1 minute time 
intervals. 
Similar HPLC assay experiments involving protein based reducing systems such 
as the thioredoxin reducing system, should be performed to represent the biological 
conditions present in the cell to understand the functionality of MsrB3A better. 
To understand the reaction mechanism of MsrB3A, several mutants needs to 
be made by identifying the conserved amino acid residues from multiple sequence 
alignment and mutating them as stated by (Kumar et al., 2002), to better 
understand the reaction mechanism of MsrB3A and the corresponding structural 
impacts on MsrB3A protein. 
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Conclusions 
7.1 Introduction 
 
Although, we can conclude from our results that the recombinant MsrB3A 
protein which was expressed and purified from the recombinant E. coli cells was 
functional and might have the correct structural conformation. Yet further 
experimental work would be essential to determine the stereo-specificity of MsrB3A 
protein, its structure and the mode of action at the functional site as discussed in 
the chapters 3 to 4.  
Despite the further works required to obtain more information to better 
understand MsrB3A, there are still many questions that are unanswered. As we have 
discussed earlier, MsrB3 protein in humans has two isoforms- MsrB3A and MsrB3B, 
which are located within the endoplasmic reticulum and mitochondria, respectively 
(Kim and Gladyshev, 2004b). This is unique only to humans, though MsrB3B 
homologue is also present within the mouse genome but not expressed in mice (Kim 
and Gladyshev, 2004a). Hence, to understand the significance of MsrB3A protein in 
the endoplasmic reticulum of human cells, it is important to work on the following 
conditions which are discussed in the following sections. 
 
7.2 Potential substrates for MsrB3A in human endoplasmic reticulum 
 
Several studies have been made to determine methionine-rich proteins which 
are the active substrates for methionine sulfoxide reductases mostly in bacteria (Le 
et al., 2008). Recent studies have also found certain methionine-rich repeat proteins 
occurring in the membrane of higher organisms (Weiss et al., 2005). However, in 
higher organisms such as the mammalian cells, the situation is more complicated. 
Due to the presence of multiple isoforms of MsrB which occur individually within 
different cellular compartments, as well as, differ in their mode of action and 
substrate affinity. Unlike bacteria, the potential substrates for the MsrB protein 
within different cellular components of the eukaryotic cells are also not clear, 
because of the diverse environment within the cellular compartments. Recently, it 
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has been reported that methionine sulfoxide reductases are more efficient in 
reducing methionine sulfoxide in unfolded proteins than in folded proteins and their 
activities increase with greater degree of unfolding in the proteins, hence, serving 
the critical function in folding of proteins by repairing the damaged nascent 
polypeptides and unfolded proteins produced due to oxidative stress (Tarrago et al., 
2012). Since, MsrB3A is present within the endoplasmic reticulum of human cells, 
hence, potential substrates found in the ER would be of great importance and play 
vital roles in understanding human diseases at molecular level.  
From sequence analysis (Fig. 3.1) it was assumed that the cysteine residue at 
the 126th position of the MsrB3A amino acid chain is an active site residue. By help of 
our experiments it could be said that the 126th position cysteine is also responsible 
for the function of MsrB3A. Yet the structural information related to MsrB3A mutants 
such as, C126A MsrB3A mutant would be essential to confirm it. Also, potential 
substrates for MsrB3A protein within the endoplasmic reticulum of human cells are 
still unknown which could provide us with more insight in to MsrB3A function. Thus, 
using site-directed mutagenesis, we can create a mutant by substituting the 
asparagine residue (conserved) at the 128th position in the amino acid chain to 
aspartate with the aim of trapping the covalent intermediate between the enzyme 
and substrate through Pummerer reaction of the bound sulfoxide. This mutant would 
then enable us to identify potential substrates for MsrB3A in cells, as any conjugate 
formed could then be isolated and identified using mass spectroscopy. 
Another advantage which could be achieved from finding the potential 
substrates would be their link with potential human disorders such as Alzheimer’s 
disease, cancer, etc., which can then be studied further to either decrease the 
detrimental effects caused by the diseases or essentially cure them.  
 
7.3 Enzyme kinetics and substrate affinity of MsrB3A within the ER 
 
From the literature, we know that, MsrB3A and MsrB3B are two isoforms of 
MsrB3 protein that occur exclusively in human due to alternative splicing, but are 
targeted to the endoplasmic reticulum and mitochondria, respectively. Genomic 
analysis of the matured MsrB3A and MsrB3B genes has revealed that presence of six 
and eight exons within MsrB3A and MsrB3B, respectively. Although the sequence of 
Page | 99  
 
MsrB3A and MsrB3B are almost identical, the presence of the extra two exons in 
MsrB3B could be the signal peptide targeting MsrB3B to the mitochondria. From the 
analysis of MsrB2 and MsrB3B activity in the mitochondria, it was noted that MsrB3B 
was highly active when the concentration of methionine sulfoxide was greater than 1 
mM. From sequence analysis, it could be clearly observed that the functional portion 
of MsrB3A and MsrB3B were identical. Hence, it can be predicted that the activity of 
MsrB3A within the endoplasmic reticulum is the same as MsrB3B (Kim and Gladyshev, 
2004b). 
 
7.4 Determination of physiological role of MsrB3A during oxidative stress 
With the identification of potential substrates of MsrB3A in the human cells 
and determination of the enzyme activity in the endoplasmic reticulum, the next 
step is to understand the physiological role of MsrB3A within the endoplasmic 
reticulum.  
Throughout the literature, there are indirect references which relate 
methionine oxidation with human disorders such as breast cancer, Alzheimer’s 
disease, human deafness with age and many other age-related disorders (Gonias et 
al., 1988, De Luca et al., 2010, Butterfield and Kanski, 2002, Ahmed et al., 2011). In 
most cases, it was observed that the oxidation of methionine residue caused by the 
ROS induced oxidative stress led to alteration in the conformation of the proteins if 
not repaired, thereby, leading to loss in essential protein function. Unless the 
oxidised methionine residues are repaired by the Msr enzymes, they tend to increase 
the oxidative stress. Studies related to over-expression of different Msrs has shown 
that there is increase in the resistance against oxidative stress, with down-
regulation of age-related disorders and increase in the life-span. For example, 
expression studies conducted on Drosophila and mammalian cells over-expressing 
the MsrB3A protein has shown to increase the oxidative stress resistance in the cells 
and increasing their life-span (Kwak et al., 2012).   
Hence, to understand the physiological role of MsrB3A within the endoplasmic 
reticulum of human cells, we need to generate knock-out cell lines from 
immortalised cell lines such as, HT1080, HEK293 or HeLa cell lines, which are 
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deficient in MsrB3A gene, using CRISPR-Cas 9 technology and then study the effects 
of the susceptibility of the ER proteins to methionine oxidation. 
 
7.5 Other areas of research 
Although, we need to perform the above experiments to have a detailed 
understanding of the role of MsrB3A within the ER of human cells, there are still some areas 
which are unknown and require further investigation. The first being that MsrB3A is 
predicted to be involved only in the reduction of methionine-R-sulfoxide. However, in 
mammals there is only one gene that encodes for MsrA and no additional genes could be 
revealed from BLAST analysis. It is still unclear whether the single gene is responsible to 
generate multiple protein products which get targeted to different cellular 
compartments or some unknown MsrA gene is still present which is yet to be found. 
Experimental studies have shown that MsrA is present in the mitochondria and 
cytosol of the cells (Hansel et al., 2002, Vougier et al., 2003). But no such evidence 
has been found that supports the presence of MsrA within the endoplasmic reticulum 
or the nucleus of the cell. A viable explanation to this could be the presence of 
certain epimerase enzyme which might be responsible for the conversion of the S-
form to R-form of methionine sulfoxide, thereby, preventing the accumulation of 
methionine-S-sulfoxide and inhibiting oxidative stress (Kim and Gladyshev, 2004b). 
Another area which needs investigation is the process by which MsrB3A 
function is recycled back. Though we will be able to know this clearly when the 
MsrB3A structure is determined, as it would provide us a detailed insight as to how 
the enzyme activity gets recycled within the ER. It is predicted that either a 
resolving cysteine is present very near to the active site cysteine or the protein 
activity is recycled by thioredoxin using the thioredoxin reductase reducing system 
which is present in the ER and would be a member of the protein disulphide 
reductase family. 
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Dissolve in 950 ml of de-ionised 
water 
 
Measure and adjust for 
required pH 
Make up the volume 
using de-ionised water 
 
Autoclave the LB media and 
store until further use 
Dissolve in 800 ml of de-
ionised water 
 
Make up the volume up to 
900 ml using de-ionised 
water 
 
Sterilise by Autoclaving and 
cool down to room temperature 
Adjust volume to 1000 ml by adding 100ml of 
filter sterilised solution (filter sterilised using 
0.22 µm Minisart® High Flow syringe filter from 
Sartorius) of 0.17 M KH2PO4 and 0.72 M K2HPO4. 
Appendix   
 
A. Luria Broth (LB) Media (1l) 
Tryptone – 10 g 
Yeast Extract – 5 g                
NaCl – 10 g  
                                                                   
 
 
 
B. Terrific Broth (TB) Media (1l) 
Tryptone – 12 g 
Yeast Extract – 24 g 
Glycerol – 4 ml 
 
 
 
 
 
C. 15N-labelleling Media (M9 Minimal Media) 
M9 medium (10X); (for 1L)                                                              
Na2HPO4 – 60 g 
KH2PO4 – 30 g 
NaCl – 5 g 
15NH4Cl – 5 g  
 
(should be freshly prepared, filter sterilised using 0.22 µm Minisart® 
High Flow syringe filter from Sartorius and added at the end in the 
final medium @ 0.6 g / (L of medium).  
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Add to 800 ml de-ionised 
water. 
Adjust pH to 7.5.  
Add to solution.  
Adjust volume to 1000 ml.  
Filter sterilise using 0.22 µm Minisart® High 
Flow syringe filter from Sartorius. 
Filter sterilised using 0.22 µm Minisart® 
High Flow syringe filter from Sartorius. 
Trace element solution (100X); (for 1L) 
EDTA – 5 g 
FeCl3.6H2O – 0.83 g 
ZnCl2 – 84 mg 
CuCl2.2H2O – 13 mg 
CoCl2.6H2O – 10 mg 
H3BO3 – 10 mg 
MnCl2.6H2O – 1.6 mg 
 
 
 
15N-labelling media 
M9 medium (10X) – 100 ml 
Trace element solution (100X) – 10 ml 
20% (w/v) glucose solution – 20 ml 
1M MgSO4 solution – 1 ml 
1M CaCl2 solution – 0.3 ml 
1 mg/ml Biotin solution - 1 ml 
1 mg/ml Thiamine solution – 1 ml 
 
Note: - The appropriate antibiotic and IPTG solution added to the media were also filter 
sterilised using 0.22 µm Minisart® High Flow syringe filter from Sartorius. 
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